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Abstract

BIOCHEMICAL EVALUATION OF LIGNIN-LIKE MOLECULES

By Jay N Thakkar, PhD

A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2011

Director: Dr. Umesh R. Desai
Professor, Department of Medicinal Chemistry

Current anticoagulants carry a serious risk of bleeding complications. In addition, narrow
therapeutic index, drug interactions, immunological reactions, toxicity and high cost to benefit
ratio limits the effective use of these drugs in patients with thrombotic conditions.

xix

Heparin is the most widely used anticoagulant. We hypothesized that one of the major
drawback of heparins, its non-specific interaction with the plasma proteins arises as a result of
negative charges. To reduce these non-specific interactions, our laboratory designed sulfated low
molecular weight lignin (LMWL) like biomacromolecules, which were found to be direct
inhibitors of thrombin and factor Xa, acting through a unique exosite-2 mediated process.
To elucidate the structural basis of this mechanism, we studied unsulfated and size
fractionated LMWLs. Detailed enzyme inhibition studies with sulfated and unsulfated LMWLs
of ferulic and caffeic acid oligomers revealed that sulfation was not absolutely critical for dual
inhibition property and smaller oligomers can yield a potent anticoagulant. Mechanistically,
unsulfated LMWLs retained exosite-2 mediated inhibition mechanism. A major advantage
expected of the unsulfated LMWLs is the possibility that orally bioavailable anticoagulants may
become possible.
To identify target specific structures within the heterogeneous population of sulfated
LMWLs, we prepared sulfated β-O-4-linked oligomer using chemical synthesis. Enzyme
inhibition studies revealed that the sulfated β-O-4 LMWL were highly selective direct inhibitors
of thrombin. These results show for the first time that specific structural features on LMWL
scaffold dictate inhibition specificity. Studies in plasma and blood display highly promising
anticoagulant profile for further studies in animals.
To further study the LMWL scaffold as macromolecular mimetic of heparin; we
investigated their effect in preventing cellular infection by herpes simplex virus-1 (HSV-1).
Based on previous findings on sulfated lignins a size-dependent study on unsulfated LMWLs
was done. The unsulfated lignins were found to not only inhibit HSV-1 entry into mammalian
cells, but were more potent than sulfated lignins. Interestingly, shorter chains were found to be as

xx

active as the longer ones, suggesting that structural features, in addition to carboxylate groups,
may be important. It can be expected that unsulfated lignins also antagonize the entry of other
enveloped viruses, like HIV-1 and HCV that utilize heparan sulfate to gain entry into cells. The
results further present major opportunities for developing lignin-based antiviral formulations for
topical use.

CHAPTER 01
Introduction
1.1

Background

Cardiovascular disease (CVD) is estimated to be responsible for 17.1 million deaths per
year, making it number one cause of death worldwide.1-4 WHO estimates that by 2030,
the number people dying from CVD, mainly heart disease and stroke is expected to reach
23.6 million. The advancement of safe and adequate treatment options for thrombotic
disorders has proven elusive for over half a century. The problem probably lies in the
complexity of the hemostatic system, which maintains the balance between thrombus
formation and blood flow primarily through the action of a serine protease known as
thrombin.5 Inhibition of this enzyme would be beneficial for the treatment and prevention
of a multitude of CVDs.6-7 Current therapies reduce the risk of recurrent CVDs but are
plagued with side effects, dosage maintenance difficulties, and undesirable delivery
methods.8 Consequently, there is significant medicinal potential for the design and
synthesis of novel anticoagulant agents that are both potent and selective with minimal
side effects.

1.2

Hemostasis

The role of hemostasis is to maintain an unimpeded flow of blood and return its fluidity
following vascular injury.5,9 A systematic understanding of the hemostatic system is
necessary in order to design and develop newer anticoagulant agents. The hemostatic
system refers to the complex interaction of plasma coagulation and fibrinolytic proteins,
platelets, and the blood vasculature.10-11 Hemostasis is further sub-categorized into; 1)
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Primary hemostasis – in this a clot is formed at the site of injury through aggregation of
platelets. 2) Secondary hemostasis – the platelet plug formed strengthens through tandem
fibrin meshwork forming via the complex coagulation cascade. 3) Tertiary hemostasis –
the clot retracts and is slowly lysed by plasmin.12 The hemostatic system is stimulated
through the activation of the fVII-tissue factor complex and the aggregation of circulating
platelets.5,10 The two responses combined produce the hemostatic plug. The controlled
occurrence of these discrete responses require coordination between the platelet and
coagulation cascade, which is attained through the employment of the plasma protease,
thrombin.13 Thus, thrombin is the vital link between these two systems.

1.3

Pathology of Improperly Regulated Hemostasis

Hemostasis is a complex balance of events which, if improperly regulated can lead to
various complications during an injury. Inadequacies in hemostasis can lead to
hemorrhage, while inappropriate or excessive hemostasis can lead to thrombosis.14-19
Both of these are complex in nature that occur in the coagulation and fibrinolytic
systems. In view of the fact that the coagulation and fibrinolytic system are inter-linked,
any distortion of the coagulation system is amplified by the fibrinolytic system.

Technically hemorrhage signify bleeding. Apart from trauma, hemorrhage can occur due
to several factors; 1) intravascular changes or decrease in the clotting factors, 2)
intramural changes caused due to aneurysms or arteriovenous malformation, and 3)
extravascular changes caused due to H. pylori infection, brain tumor or abscess.14-15
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Other factors that can cause bleeding are drugs such as NSAIDs, which inhibit production
of thromboxane and activation of platelets.16-17

Thrombosis implies formation of a blood clot, which eventually blocks the circulation of
blood flow. Thrombosis can occur due to several factors; 1) genetic deficiencies or
autoimmune disorders leading to hypercoagulability, 2) exposure of tissue factor (TF) to
the blood coagulation system caused during trauma, surgery or infection and 3) disturbed
blood flow, which can occur due to long periods of sedentary behavior (eg: traveler’s
thrombosis), atrial fibrillation, venous stasis, obstruction of blood flow, certain type of
cancers and cancer therapies. 18-19

A large percentage of population is at risk of developing a pathological thrombus whether
in the form of a stroke, venous thromboembolism, or arterial thrombosis.20 Generally
speaking, undesirable clots are a result of unregulated or unwarranted generation of
thrombin, leading to an increase in thrombin-activable fibrinolysis inhibitor (TAFI)
activation. Excessive TAFI activation would extenuate fibrinolysis and consequently
hinder the restoration of blood flow in a timely manner.21-22

1.4

The Coagulation Cascade

The coagulation cascade is a complex ordered set of proteolytic events that occurs in the
body when a blood vessel is injured (figure 01).23 Each enzyme of the coagulation
pathway is present as a protease zymogen in plasma, which on activation undergoes
proteolytic cleavage to discharge the active factor from the antecedent molecule.24 The

3

activation is functional through a series of positive and negative feedback loops.
Eventually, the pathway leads to production of thrombin, which promotes fibrin
formation to form a clot, thereby down regulating the procoagulant activity.25 Thrombin
generation occurs via two pathways, the intrinsic and the extrinsic pathway, which
converge at fX to a single common pathway resulting in the production of thrombin
(fIIa). 26

fXII

fXIIa
fVIII
fXI

fXIa

TFPI

APC

fIIa

TF

fV
fIX

fIXa fVIIIa

fIIa

fX

fVa

fXa

TF+fVIIa fVII

fXa

fX
AT

fII

(prothrombin)

CLOT

fIIa

(thrombin)

fIa

fXIIIa

fI

(fibrin ) (fibrinogen)

fIIa

fXIII
Sub-endothelial surface

Prekallikrein

HMWK

endogenous inhibitors

Figure 01. Simplified coagulation cascade
HMWK - high molecular weight kininogen; AT – antithrombin; APC – activate protein C and
TFPI – tissue factor pathway inhibitor
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1.4.1 Intrinsic Pathway
It is also called as the contact pathway, and is less significant and not very well
understood in terms of its role in hemostasis under normal physiological conditions.23,27
The contact pathway gets its name from the fact that the coagulation system is activated
to form a clot when blood comes into contact with negatively charged surfaces or with
sub-endothelial connective tissues.28 The first step is binding of fXII (Hageman factor) to
the sub-endothelial surface followed by an injury. Prekallikrein, and high molecular
weight kininogen (HMWK) also bind at the surface activating fXII to fXIIa. During this
activation fXII is cleaved into two chains, which stay connected through a disulfide
bond.29 The lighter of the two chains contain the active site and is termed as the activated
fXII (fXIIa).29 fXII can auto-activate or activate through a feedback mechanism by
activating prekallikrein thus amplifying the pathway. fXIIa then activates fXI to fXIa in
presence of HMWK and Ca+2 ions secreted from platelets. fXIa in turn catalyzes the
conversion of fIX to fIXa in presence of Ca+2 ions. Eventually, fX is activated to fXa, a
process that can also occur through the extrinsic pathway. fX activation is brought about
by a molecular complex containing fIXa, fVIII, Ca+2 ions and phospholipids provided by
the platelet surface, where this reaction usually takes place.25 The precise role of fVIII in
this reaction is not clearly understood. Its presence in the complex is obviously
indispensable, as seen by the serious consequences of fVIII deficiency experienced by
haemophiliacs.30 fVIII is altered by thrombin, to its activated form, promoting the
activation of fX. Although the physiological contribution of the contact pathway to
coagulation remains elusive, recent data suggest that it plays some role in physiological
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blood coagulation, since mice deficient in fXII have been shown to be protected against
both stroke and arterial thrombosis.31

1.4.2 Extrinsic Pathway
It is also called as the TF pathway and is the major physiological pathway for fibrin
formation.23,27 It provides a swift response to tissue injury, generating fXa almost
instantaneously, as opposed to the seconds or even minutes required for the intrinsic
pathway to activate fX.32 The main function of the extrinsic pathway is to enhance the
activity of the intrinsic pathway.32 The pathway sets in at the site of injury in response to
the release of the procoagulant, TF, which is present in most human cells bound to the
cell membrane.23,27,32 The activation process for TF is not clearly understood. On
activation, TF binds rapidly to fVII activating it to form a TF + fVIIa complex, which in
presence of Ca+2 ions and phospholipids instantaneously activates fIX and fX. fXa can
further activate fVII, which forms the link between the two pathways along with fIX
activation.25

1.4.3 The Common Pathway
This is the most crucial step in the coagulation cascade, which harbors fX (fXa) and is
responsible for thrombin generation.23,26 Through the sequential activation of several
zymogens in the extrinsic and the intrinsic pathway, prothrombin (fII) is ultimately
activated via fXa and the prothrombinase complex (fVa, prothrombin, phospholipids and
Ca+2 ions). The prothrombinase complex activates prothrombin to thrombin (fIIa)
300,000-fold more efficiently that fXa alone.33 The fundamental role of thrombin is
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conversion of fibrinogen (fI) to fibrin (fIa) to form a fibrin mesh-work, which are
eventually cross-linked by fXIIIa to form a stable fibrin clot.25-26 In addition, thrombin
also activates fVIII, fV and their inhibitor, protein C (1000-fold higher in presence of
thrombomodulin) and FXIII.34 Following activation of the either pathways the
coagulation cascade is maintained in a prothrombotic state by the persistent activation of
fVIII and fIX to form the tenase complex, until its down-regulation by the anticoagulant
pathways. The three major endogenous anticoagulants in our body are antithrombin III
(AT), activated protein C (APC) and tissue factor pathway inhibitor (TFPI).35

1.5

Fibrinolysis

The clot formed as a result of an injury does not stay for ever. Gradually, the blood clot is
reorganized and reabsorbed by a process termed fibrinolysis (figure 02).23 This is
accomplished by a non-specific proteolytic enzyme, plasmin. Tissue-type plasminogen
activator (tPA) secreted from endothelial cells and urokinase activates the zymogen
plasminogen (Pg) to form the serine protease plasmin, which is responsible for degrading
the fibrin clot and restoring the blood fluidity.36-37 Analogous to the coagulation cascade a
series of stepwise events occur during fibrinolysis, which involves a fine balance between
plasmin/antiplasmin and thrombin/thrombomodulin activities.38 In essence, coagulation
and fibrinolysis systems work in cooperation to maintain hemostasis at the site of injury
while ensuring fluidity of the blood elsewhere.
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PLASMINOGEN
tPA

UROKINASE

antiplasmin
PLASMIN

FIBRIN

FIBRIN
DEGRADATION PRODUCTS

THROMBIN

TAFI

Figure 02. Fibrinolysis mechanism
tPA – tissue-type plasminogen activator; TAFI – thrombin-activatable fibrinolysis inhibitor
Blue arrows denote stimulation and red lines inhibition.

1.6

Thrombin and the Coagulation System

Thrombin has been termed as the master regulator enzyme in blood coagulation.39 It is
the last enzyme in the coagulation cascade and its ultimate product is a formation of a
stable clot.26 Thrombin, a trypsin-like serine protease ensues from the circulating
zymogen precursor protein, prothrombin.40-41 Prothrombin cleaves to form an enzyme
with an overall ellipsoid-like structure comprising of a small A-chain and a catalytic Bchain.42-43 The catalytic activity of thrombin is not only dictated by its active site but also
by recognition sites (exosite-1 and exosite-2), which modulate the specificity of the
enzyme.40,44 Understanding of the interactions between thrombin and its substrate is
crucial in the identification and design of novel medicinal agents that would interact and
regulate the activity of the enzyme (figure 03). An interesting aspect of thrombin in the
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hemostatic system is its contrasting dual nature where it acts as both an anticoagulant and
a pro-coagulant.5 Activity of thrombin is primarily controlled by two systems; 1) AT and
2) protein C and protein S.

The major regulator of thrombin activity is the plasma serine protease inhibitor (SERPIN)
AT. AT directly interacts with the active site of thrombin as well as the other major
coagulation enzymes (factors Xa, VIIa, IXa, XIa, XIIa, and plasma kallikrein) hampering
the formation of both the tenase and prothrombase complexes.5,26 Heparin cofactor
accelerates the inhibition of thrombin by AT with a 1,000-fold greater potency.5,45

fV/fVIII/fXI

fVa/fVIIIa/fXIa

PROTEIN C

PAR 1 & 4

THROMBIN
APC

FIBRINOGEN

PLATELET
ACTIVATION

FIBRIN
fXIIIa
CLOT

Figure 03. Critical role of thrombin
APC – activate protein C; PAR – protease activate receptor.
Blue arrows denote stimulation and red inhibition.
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fXIII

THROMBIN

Protein C is activated by thrombin to activated protein C (APC), which is further
enhanced in presence of endothelial protein C receptors and thrombomodulin. APC
inactivates fVa and fVIIIa, two cofactors of thrombin, thus reducing the rate of thrombin
formation.5,45 Protein S acts as a cofactor for APC, and serves as APC’s receptor to
localize its inhibitory role. The anticoagulant role of thrombin is dependent on a finite
number of thrombomodulin binding sites.45-46 When these sites are exceeded, it converts
thrombin into a physiologic pro-coagulant enzyme. Heparin cofactor II, a SERPIN is a
specific thrombin inhibitor whose activity is potentiated by the glycosaminoglycan
(GAG), dermatan sulfate.47

Although the enzymatic role of thrombin in the hemostatic process is significant and
impressive, it also has many other biological roles that are far more intricate.48-49 Some of
these include the role of thrombin in platelet activation and aggregation.50-51 Two
substrates on human platelets, protease-activated receptors 1 and 4 lead to platelet
activation when stimulated.52-53 Platelets have the ability to aggregate at the site of injury
which leads to the development of acute myocardial syndrome and coronary artery
occlusion. The non-hemostatic role involves the stimulation of chemotaxis of white blood
cells (WBC), generation and discharge of cytokines, fibroblast proliferation and
mitogenesis.54-56 Effects of thrombin on endothelial cells leads to the release of a variety
of biological mediators.49,57-58 Although not well defined, evidence of a role in cancer cell
adhesion has been speculated.59
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1.7

Anticoagulant Treatment

Thrombin plays a crucial role in coagulation of blood, hence prophylaxis or treatment of
thromboembolic disorders aim to block thrombin generation or inhibit thrombin’s
activity. There are two primary approaches employed by drug researchers in designing
anticoagulants; 1) to directly inhibit thrombin with active site inhibitors or allosteric
modulators such as hirudin and 2) to impede formation of thrombin by inhibiting the
precursors in the coagulation cascade or by disrupting the metabolic pathway (indirect
inhibition) such as heparin.60-61

Indirect inhibitors such as coumarin, dicoumarol, and warfarin are vitamin-K antagonists
and have been some of the most commonly administered anticoagulants (figure 04).
These agents work by inhibiting synthesis of biologically active forms vitamin-K
dependent clotting factors (fII, fVII, fIX, fX, protein C and protein S) of the coagulation
system.62-63 Carboxylation of these coagulation factors enhances their binding to

A)

B)

Figure 04. Vitamin-K antagonist indirect inhibitors of thrombin
A) coumarin and B) warfarin

phospholipid surfaces, thereby accelerating blood coagulation.64 For example, warfarin
inhibits the vitamin-K epoxide reductase, which hampers the formation of reduced
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vitamin-K required for γ-carboxylation of these clotting factors.64-65 Heparin and low
molecular weight derivatives of heparin (LMWH) are other indirect inhibitors frequently
used in clinical settings (figure 05).66 Heparin is a sulfated GAG produced by mast cells,
which activates the endogenous anticoagulant, AT.67 Specific sequences in heparin and
LMWH bind AT and bring about a conformational change in the endogenous inhibitor
that leads to 1,000-fold acceleration in the rate of AT activity.67-68 This is a two step
process, which includes accelerated inhibition of fXa followed by a bridging mechanism
of heparin, which brings thrombin and AT into close proximity.62,69 The mechanism of
inhibition varies slightly for each protease.

Figure 05. AT activator indirect inhibitors of thrombin
Heparin and low molecular weight heparins (LMWH)

Direct thrombin inhibitors such as hirudin, recombinant hirudin (lepirudin and desirudin)
and bivalirudin bind at the active site and exosite I; whereas, argatroban and ximelagatran
bind exclusively at the active site of thrombin bringing about disruption of the catalytic
arsenal leading to cessation of thrombin activity (figure 06).70-73
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A)

B)

Figure 06. Direct inhibitors of thrombin
A) Argatroban and B) Ximelagatran

1.8

Medical Role of Anticoagulant Therapy

The most promising application of a novel anticoagulant agent would be prevention of
acute coronary syndrome (ACS), stroke and venous thromboembolism (VTE). ACS is an
umbrella term covering a spectrum of clinical conditions ranging from unstable angina to
acute myocardial infarction.74-75 About every 26 seconds, an American encounters a
coronary event, and about every minute one will die as a result of an acute thrombus
obstructing the coronary artery.76 A stroke, sometimes called a brain attack, occurs when
a clot blocks the blood supply to the brain or when a blood vessel in the brain bursts.77
Approximately 25% of all strokes are associated with aberrations in the cardiovascular
system.78 These abnormalities lead to the development of a secondary embolus that
blocks the cerebral circulation resulting in ischemia and neuronal damage.79-80
Cardioembolic strokes can be treated with anticoagulants following atrial fibrillation,
intracardial thrombus or endocarditis.81 About every 40 seconds someone in the US has a
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stroke and every 4 minute someone dies of stroke.76 VTE, 3rd most common cardio
vascular (CV) illness refers to a number of medical conditions that result from abnormal
thrombosis including deep vein thrombosis (DVT) and pulmonary embolism (PE).62
About 1 million people are affected by VTE in the US alone.77 VTE is caused by three
major factors: blood hypercoagulability (excessive clotting), blood-flow stasis
(immobility), and vessel wall damage (atherosclerosis).62 Therefore, by modulating the
activity of the hemostatic system, we can attempt to treat and prevent these serious and
often fatal medical conditions. Novel anticoagulants that are safer and effective can
potentially treat these conditions by inhibiting the circulating detached thrombi in
patients

with

high

risk

factors

such

as

race,

hypertension,

diabetes,

and

hypercholesterolemia.78 Anticoagulant treatment is absolutely requisite in patients with
predisposition for these conditions. Current available anti-thrombotic treatments require
constant clinical monitoring due to the variation in individual response to the drugs.79
These remedies minimize the risk of recurrent cardiovascular episodes, but accompany
the risk of bleeding in part because they act systemically.79 A new generation of
anticoagulants with better efficacy and fewer side effects could potentially revolutionize
the treatment options for thrombotic disorders.

1.9

Limitations of Current Anticoagulant Therapy

The current anticoagulant therapies are plagued with several limitations; heparin has poor
subcutaneous absorption, variable effect due to binding to multiple plasma proteins, and
the development of thrombocytopenia (decrease in normal levels of platelets).62-63,80
LMWH, synthesized in an effort to improve the bioavailability and overcome the non-
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specific plasma proteins interaction must be administered subcutaneously limiting their
use for outpatient therapy, in addition the patient needs to be monitored on regular
basis.63,80 Smaller molecules and peptide derivatives suffer a set back due to one or
several of the following factors; drug-drug, drug-food interactions, narrow therapeutic
window, significant bleeding risk and inability to inhibit clot bound thrombin.81 The need
to develop highly desirable anticoagulants and an extensive knowledge of the coagulation
cascade has guided the researchers to focus their attention on the common pathway of the
coagulation system. In theory, any single enzyme in the coagulation cascade could be
targeted to bring about the anticoagulation effect. However, fXa and thrombin, that are
common to both the intrinsic and the extrinsic pathway, can be targeted resulting in a
more effective anticoagulant.82 Designing direct inhibitors of fXa appears to be an
improved strategy to eliminate most of the side effects of current anticoagulants and
make it viable to inhibit both the circulating as well as platelet bound fXa without
affecting the platelet function.83 Further, selective direct inhibitors of thrombin called as
direct thrombin inhibitors (DTIs) can be designed to inhibit the free circulating as well as
the clot bound thrombin.63,84 Inhibitors of thrombin and fXa are fertile areas of
exploration and are further advanced in development than most other candidates.85-86

1.10

Direct fXa Inhibitors

The amount of an activated coagulation factor produced from its inactive precursor
amplifies at each stage of the coagulation cascade. Consequently, targeting fXa in the
common pathway could be an effective approach for developing newer anticoagulants
(figure 07).87 In addition, fXa is known to be the primary site of amplification; one
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molecule of fXa catalyzes the formation of ~1000 thrombin molecules.88 Currently
available fXa inhibitor work through AT mediation, hence called indirect inhibitors
(Fondaparinux and Idraparinux).89-90 Direct fXa inhibitors (eg: rivaroxaban and apixaban)
are AT independent and are 10,000 fold more selective for fXa over other related
proteinases (figure 08).91-93 fXa inhibition results in down regulation of thrombin
formation (not thrombin activity) via both the pathways by blocking the interaction with
prothrombin.94 This allows the circulating thrombin to perform its vital functions, thus
potentially maintaining hemostasis at sites of hemostatic challenge. Another advantage of
direct fXa inhibitors is that it inhibits free fXa as well as platelet bound fXa, which is part
of the prothrombinase complex and clots.94 Outside the coagulation system fXa has
shown to exhibit proinflammatory activity.95

Indirect inhibitors

Direct inhibitors

Extrinsic

-Heparins
-LMWHs

AT mediated

Intrinsic

-Apixaban
-Betrixaban

fXa
fXa

(bound in prothrombinase-complex)

Prothrombin

thrombin

fibrinogen

-hirudin
-argatroban

fibrin

Figure 07. Pivotal position of fXa and thrombin in the coagulation cascade and mode of
action of a few fXa and thrombin inhibitors.
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A)

B)

Figure 08. Chemical structures of direct fXa inhibitors
A) Rivaroxaban and B) Apixaban

1.11

Direct Thrombin Inhibitors (DTIs)

Given the fundamental role thrombin plays in vasculature and platelet signaling, it can be
rationalized that DTIs would have a positive outcome on vascular physiology. The most
critical aspect related to thrombus formation is the evasion of clot bound active thrombin
from its inhibitors such as heparin.96 Thrombus thus serves as a reservoir of active
thrombin, which amplifies its own generation by activation of fV, fVIII and fXI.97 It can
further stimulate thrombus growth by locally activating platelets and converting
fibrinogen to clottable fibrin.25-26 It activates fXIII to form stable clots and enhance
resistance to fibrinolysis.25-26 In addition, after discontinuation of heparin therapy, there
can be a reactivation of the coagulation system as the fibrin-bound thrombin reactivates
fX within the thrombus, prompting further thrombin generation.98 Thrombin inhibition
could thus lead to multiple effects for anticoagulation. DTIs (hirudin, lepirudin,
argatroban, dabigatran) require no preceding interaction prior to their action on thrombin
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unlike the indirect acting, which require AT mediation (refer figure 07).70-73 DTIs put a
check on thrombin from interacting effectively with its substrates thus prevent fibrin
formation, obstruct thrombin-mediated feedback activation, delimit thrombus growth,
inhibit activation of platelet factor 4 (PF4), protein C and many other functions of
thrombin.99

Thrombin also plays an important role in inflammation and cellular proliferation where
DTIs may represent an adjuvant therapy (figure 09).100 DTIs can be univalent (interact
with one site) or bivalent (interact with 2 sites).101 Unlike direct fXa inhibitors DTIs fail
to block thrombin generation. Both the DTIs and direct fXa inhibitors will provide more
predictable anticoagulant responses because they are not bound to plasma proteins.

Anticoagulant
Protein C activation
Prostacyclin formation

Procoagulant
Platelet, TAFI & feedback activation
Fibrin formation

THROMBIN

Cellular proliferation
Tissue repair
Growth factor secretion
Angiogenesis

Inflammation
Cell adhesion
Chemotaxsis
P-selection expression

Figure 09. Various functions of thrombin within and outside the coagulation cascade82
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1.12

Limitations of Current Direct fXa and Thrombin Inhibitors

DTIs, like hirudin, form a nearly irreversible bond with the enzyme.71 An improvement in
form of bivalirudin acts as a selective and reversible inhibitor of thrombin however;
problems with parenteral delivery and rapid clearance have limited its use for a wider
range of conditions.102 These issues were addressed by new class of DTIs like
melagatran, but were unsuitable for oral administration.103 A prodrug of melagatran in
form of ximelagatran had hepatotoxic and adverse cardiac effects.104 In late 2010,
USFDA had approved dabigatran but not without an added caution “life-threatening and
fatal bleeding”.105 The oral fXa inhibitors have variable and transient effects on the
prothrombin time.106 A potential drawback of the newer anticoagulants is the lack of
specific antidotes, shorter half life and lack of lab markers to monitor the drug activity.107
Additionally, since there are no routine monitoring tests it will be difficult to determine
whether suboptimal results are due to failure of therapy or poor patient compliance. It is
evident that newer agents may change the future of anticoagulation therapy and provide
improved patient care. With new opportunities will come new challenges, but the benefits
of new oral anticoagulant offsets any drawbacks. The results of clinical trials with DTIs
and direct fXa inhibitors validate both thrombin and factor Xa as potential targets, and
there is no convincing evidence that one target is better than another.108 Head-to-head
comparisons will reveal any meaningful differences in efficacy or safety among the
newer agents. Such assessment seems unlikely because of potential commercial risks.
Even if one exhibits the superiority in targeting over the other, the variation will be more
reflective of the dose and the pharmacological properties of the drugs rather than the drug
target.
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1.13

Bifunctional Inhibitors

From the preceding discussions it is clear that neither the DTIs nor direct fXa inhibitors
can inhibit both generation and circulating (free and bound) thrombin, the mainstay in the
formation of a clot. Hence, the theory of bifunctional inhibitors has been conceived,
which will inhibit both the serine proteases simultaneously in the common pathway. Both
the proteases can be inhibited by co-administering inhibitors specific for the enzymes.
This proposition is not cost effective and will require preclinical and clinical trials to
study drug interactions and side effects.109 The other viable way for simultaneous
inhibition of both the proteases is to design an inhibitor that would directly inhibit both
thrombin and fXa. Such inhibitors with dual functionality are termed as bifunctional
inhibitors. Bifunctional inhibitor is not a new concept in the field of anticoagulation,
UFH inhibits both thrombin and fXa via the AT mediation. The disadvantage UFH
carries along is its non-specific binding interactions with other proteins in the system
leading to numerous side effects.110 There are no bifunctional anticoagulant drugs on the
market, though a few are in the drug discovery phase.

1.14

Structure of Thrombin

Thrombin has distinctive structural features that control specificity. A closer look at the
surface reveals uneven charge distribution with localized positively and negatively
charged pockets in (figure 10).111-112 There are four distinct binding sites on thrombin as
depicted in figure 11. These sites recognize a variety of different molecules and present
the diverse functions of thrombin.40,44 All of the physiologic effects of thrombin are a
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direct result of its catalytic activity.114 Substrate specificity, however, is determined by
several accessory binding domains that exist in clusters.114

1.14.1 Active site
This is the substrate binding site, which also mediates interactions with fibrinogen,
protein C and AT-III. 112 The active site of thrombin is very similar to that of trypsin and
chymotrypsin.40-41 There are deeply situated specificity pocket (S1) that consists of the
catalytic triad Ser195-His57-Asp102 surrounded by hydrophobic residues at the rim.
Asp189 lining the S1 pocket electrostatically interacts with cationic substrates. S2 and S3
pockets are more hydrophobic and acidic respectively while the S4 pocket has a
preference for aliphatic groups.112

Figure 10. Thrombin surface electron density map with electrostatic potentials.113
The more basic the protein surface, the more red that area appears.
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1.14.2 Exosite I
Also called as fibrinogen binding site, it is an anionic binding electropositive site.112
Exosite I recognizes carboxyl terminal domain of hirudin, hirudin-like region of PAR-1
and fifth and sixth EGF-like domains of thrombomodulin.115 It is located to the right of
the thrombin active site cleft, mainly placed on the 70 to 80 loop and bordered by the 37loop and segment Lys109-Lys110. In its center, the exposed side chains of Tyr76 and
Ile82 form a hydrophobic cap, which is surrounded by side chains of several lysines and
arginines interspersed by a few hydrophobic side chains. The strong positive charge is
only partially compensated by the acidic residues Glu77 and Glu80 involved in an ionic
cluster beneath the surface.112
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Figure 11. Cartoon representation of thrombin showing the four binding sites and different
molecules recognizing them.113
Heparin binds at the exosite-II, hirudin binds to both the active site and fibrinogen recognition
site (exosite-I) melagatran and argatroban binds at the active site.
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1.14.3 Exosite II
Also called as the heparin binding site, it is the second electropositive, anionic binding
site located opposite to exosite I.112 Exosite II recognizes carboxyl terminal region of Bchain of thrombin and highly sulfated polysaccharide like heparin and chondroitin sulfate
of thrombomodulin.116 At this surface, a small hydrophobic Leu234-based channel is
surrounded by basic residues Arg93, Arg101, Arg165, Arg233, Arg126, Lys236, Lys235,
Lys240, and His91, with most of their side chain charges not compensated by adjacent
negative charges. This uncompensated strong electropositive charge attracts polyanionic
molecules like heparin to recognize exosite II.112

Both exosites differentially influence the active site and this allosteric effect plays a
major role in the specificity and reactivity of thrombin towards its macromolecular
substrates.117 Exosites are located at approximately opposite ends of the thrombin
molecule and approximately 10–20 Å away from the active site.117

1.14.4 Sodium ion binding site
+

Na ion binding site has been confined to a site in the center of the 222 loop situated in a
solvent-filled cavity behind the S1 specificity pocket located near Asp189.112 The bound
+

Na ion, located more than 15 Å away from the catalytic triad, is coordinated in an
octahedral manner by the carbonyl oxygens of Arg221 and Lys224 and by four internal
water molecules, and is further stabilized by the negative charges of Asp221 and
+

Asp222.112 Thrombin has greater catalytic efficiency in the presence of Na ions than in
+

the absence of Na ions.
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1.15

Structure of fXa

The active site of fXa is smaller and less hydrophobic than the active site of thrombin.118
Refer figure 12 for active site of fXa. The active site is divided into four sub-pockets, S1
to S4. The major component of selectivity and binding is attributed to S1 sub-pocket. The
S2 sub-pocket is small, shallow, not well defined and it merges with the S4 sub-pocket.
The S3 sub-pocket is solvent exposed located on the rim of the S1 pocket. The S4 subpocket has three ligand binding domains, namely the hydrophobic enclave, the cationic
hole and the water site. fXa inhibitors commonly bind in an L-shaped conformation,
where one group of the ligand occupies the anionic S1 pocket lined by residues Asp189,
Ser195, and Tyr228, and another group of the ligand occupies the aromatic S4 pocket
lined by residues Tyr99, Phe174, and Trp228. Typically, a fairly rigid linker group
bridges these two interaction sites.118

Figure 12. Active site of fXa with key residues displayed113
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1.16

Conclusion

Normal hemostasis is essential for regulation of blood flow. An improperly regulated
hemostasis can cause hemorrhage or thrombosis leading to life threatening conditions.
Thrombosis occurs due to excessive hemostasis and a thrombus thus formed can lead to
stroke, venous thromboembolism or arterial thrombosis, which are leading causes of
death worldwide. Thrombus formation is a product of excessive generation of thrombin
in the coagulation cascade, which in turn is regulated by numerous other coagulation
enzymes. In the coagulation cascade, activating the AT or inhibiting the up-regulated
coagulation enzymes in intrinsic and extrinsic pathways can be targeted to indirectly
impede the formation of thrombin. Current antithrombotic agents that work through
indirect inhibition prevent the formation of thrombus, thus reducing the risk of recurrent
cardiovascular events but not without serious side effects. The major set back is the nonselectivity of these drugs for the target and their inability to inhibit clot bound thrombin.
Targeting fXa and thrombin, which are common to both the intrinsic and extrinsic
pathways could result in a better anticoagulant as they would inhibit both free and clot
bound thrombin. Direct fXa and thrombin inhibitors are fertile areas of research where a
mono- or bifunctional inhibitors concept has been envisioned but has been largely
remained unsuccessful in delivering an ideal anticoagulant. Hence, there still exists the
need to design a potent anticoagulant with minimal side effects.
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CHAPTER 02
Identification of an Optimum Size of DHP as a Lead for Structure-based Drug
Design

2.1

Background

Hypercoagulability increases the risk of inappropriate or excessive thrombus (blood clot)
formation resulting in serious disseminated intravascular coagulation (DIC), venous
thrombosis, thromboembolism, cardiovascular complications, or in some cases multiple
organ failure.62,74-75,81 Current anti-thrombotic therapies are able to reduce the risk of
recurrent cardiovascular events, but not without serious side effects, the most widespread
of all being bleeding.62-63,80 One of the major reasons for this has been attributed to the
non-specific binding of these drugs to plasma proteins. 62-63,80 The quest to discover more
cost effective and safer drug has led researchers to explore deeper into understanding the
specific mechanism and role of each step in the entire coagulation system. Years of
research and experience has resulted in numerous drugs targeting different and multiple
coagulation factors, yielding an enhanced perception of the need for development of
better and efficient drugs. Specifically targeting the common pathway in the coagulation
cascade is one such fruit of our conception. There are few drugs that specifically act on
the proteinases, thrombin and fXa in the common pathway but most are in pre-clinical or
clinical evaluation stage.70-73,89-93 These and the ones that are approved continue to inherit
the complications from their early ancestors. Hence, the need still exists to develop new
and improved anticoagulant agents that would eliminate the poor traits of their early
ancestors.
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Advancement in this direction has been challenging as there are numerous hurdles that
have been dragging back the entire drug development process. It is important that the
new drugs reduce excessive bleeding, liver toxicity, inhibit both free and clot-bound
thrombin. It also necessitates investigating, which inhibition strategy will yield more
efficient results in inhibition of thrombin, the ultimate and pivotal proteinase in the
coagulation cascade. Will inhibiting either of the one proteinase, thrombin and fXa or
simultaneous inhibition of both would be more efficacious? We don’t know but
regardless, numerous unanswered questions make the field anticoagulation drug design
extremely exciting, compelling and challenging.

2.2

Rationale

All the anticoagulants used today have severe side effects, which may even lead to death.
The most common anticoagulants used for treatment of thrombotic disorders are heparin
in its unfractionated form or LMWH and coumarins (warfarin).63,80 The heparins have
risks of bleeding and heparin-induced thrombocytopenia (HIT).80,118 Fondaparinux and
idraparinux, a heparin pentasaccharide; peptidomimetics like agratroban, ximelgatran and
razaxaban; and hirudins like desirudin and bivalirudin showed to lower these risk factors
but still possessed the negative traits of their precursors.70-73,89-93 In addition, patient
variability, narrow therapeutic index, drug-interactions, immunological reactions, liver
toxicity and high cost to benefit ratio limits the effective use of these drugs in patients
with thrombotic conditions.81
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For more than three decades the anticoagulant drug discovery has revolved around
heparin and its derivatives, possessing a polysaccharide backbone. Our lab has take a step
forward in this field by designing molecules, which are not heparin-based (nonpolysaccharide) and they act through either through activation of AT or direct inhibition
of thrombin and fXa.119-121 As a proof of concept our lab has shown that linear
polyacrylic acids (PAA), which have only the carboxyl functionality, were able to bind
AT with poor affinities resulting in acceleration of the inhibition of thrombin and fXa. 122123

PAA do not have a polysaccharide backbone and they are devoid of sulfates too!

Later, to improve the affinity a more rigid skeleton like a phenyl ring with functional
group that can be derivatized to a sulfated was chosen. The carboxylic functionality was
retained for it to be amenable for structural modification to be transformed into an orally
available drug. Based on these features three types of synthetic lignins called as
dehydropolymers (DHPs) were synthesized enzymatically and later sulfated.124-125 The
three precursors chosen for enzymatic reactions were caffeic acid, ferulic acid and sinapic
acid and the sulfated polymers were termed as CDS, FDS and SDS. DHPs are structurally
dissimilar from all the current anticoagulants. The oligomeric, polyanionic, polydisperse
and micro-heterogeneity of DHPs are similar to that of heparin while the aromatic
backbone is a distinct feature. All three DHPs showed direct dual inhibition of thrombin
and fXa through exosite-2 mediation on thrombin.123-124 CDS was the most potent of the
3 DHPs and SDS the least. It has also been shown that the unsulfated DHPs were a
weaker anticoagulant as compared to its sulfated counterpart.123
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DHPs as a dual inhibitor were completely a new class of anticoagulant and it was
imperative to determine what in this mixture could have dictated the activity. This
inspiration comes from heparin where a specific sequence such as the pentasaccharide
dictates its activity as an anticoagulant (figure 13). To elucidate this aspect we conducted
chain length dependence studies on our sulfated and unsulfated DHPs. This chapter talks
about the importance of the sulfates groups in context of our DHPs and the effective size
of a working lead molecule, which would be a more potent anticoagulant possibly
carrying fewer side effects.

Figure 13. Structure of pentasaccharide binding sequence.

2.3

Experimental Methods

2.3.1 Proteins, biologicals and chemicals
Horseradish peroxidase (HRP) with activity of 250–600 330 U/mg (Sigma, St. Louis,
MO). Human plasma proteinases, fXa, and α-thrombin (Haematologic Technologies,
Essex Junction, VT). Chromogenic substrates purchased from American Diagnostica
(Greenwich, CT): Spectrozyme fXa (Methoxycarbonyl-Dcyclohexylglycyl-Gyl-Arg-pnitroanilide) Spectrozyme TH (H-Dhexahydrotyrosol-Ala-Arg-p-nitroanilide). Stock
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solutions of proteins were prepared as follows: For fXa 20 mM Sodium phosphate buffer,
pH 7.4, 0.1mM EDTA, 0.1% PEG 8000 For thrombin 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl and 2.5 mM CaCl2, 0.1% PEG 8000. Pooled citrated human
plasma for coagulation time assays (Valley Biomedical Winchester, VA). Activated
partial thromboplastin time reagent containing ellagic acid (APTT-LS), thromboplastin-D
and 25 mM CaCl2 (Fisher Diagnostics Middletown, VA). Competitive ligands used Exosite 1 ligand Tyr63-sulfated hirudin-(54-65) labeled with 5-(carboxy)fluorescein
([5F]-Hir[54-65](SO3-)). Exosite 2 ligand unfractionated porcine heparin (Sigma-Aldrich
St. Louis, MO). 30% hydrogen peroxide, TEAST complex, ferulic acid (FA) and caffeic
acid (CA) were from Sigma (St. Louis, MO). Enoxaparin (MR 4,500) (Aventis
Pharmaceuticals). All other chemicals were of analytical reagent grade from either
Aldrich Chemicals (Milwaukee, WI) or Fisher (Pittsburgh, PA) and used without further
purification.

2.3.2 Oxidative coupling and sulfation of 4-hydroxycinnamic acid derivatives
The DHPs of CA and FA were prepared by the so-called ‘zutropfverfahren’ procedure.
Briefly, in a three-neck flask slow addition of 200mL CA or FA (25mM in 10mM sodium
phosphate buffer pH 8.0) and 100mL H2O2 (75mM in the same buffer) to a 50mL
solution of HRP (10mg in the same buffer) was carried out at room temperature (RT) and
in dark over a period of 5 hours. Three additional aliquots of H2O2 (75 mM) were added
over the next 72 h. At the end of polymerization the solution was freeze-dried,
redissolved and desalted to obtain the CD and FD polymers.
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DHPs were sulfated with TEAST complex. Briefly, the lyophilized DHP sample (50 mg)
was dissolved in dry DMF (15 mL) containing TEAST (200 mg) and stirred for 24 h at
60 °C. After the removal of most of the DMF in vacuo, the remaining product was taken
up in 30% aqueous sodium acetate, the sodium salt precipitated using ~10 volume of cold
ethanol. The precipitated product was further purified with dialysis using Amicon dialysis
membrane (MWCO 3-30K).

2.3.3 Fractionation of CD and FD using centrifugal filtration
The polymerization reaction mixture was dissolved in deionized water and filtered
through Millipore filter (NMWC 30 kDa) at 4000 g. Filtration was continued until the
retentate volume was approximately 200 μL. This process was repeated five more times
and the final retentate was labeled as F30 fraction. The filtrates from the above process
were pooled, lyophilized, redissolved in deionized water and then further fractionated in
the manner described above using a 10 kDa filter. The retentate so obtained was labeled
as F10 fraction. This process was repeated to obtain F5 and F3 fractions using 5 and 3
kDa membranes. The retentates were collected and lyophilized to obtain four fractions in
yields of 15-20, 5-8, 3-5, and 1-2%, respectively.

2.3.4 Sulfation of the DHP fractions
All the DHP fractions were sulfated using triethylamine–sulfur trioxide complex. Briefly,
each fraction of DHP sample (50 mg) was dissolved in dry DMF (15 mL) containing
triethylamine–sulfur trioxide complex (200 mg) and stirred for 24 h at 60 °C. After the
removal of most of the DMF under high vacuum, the remaining product was taken up in
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30% aqueous sodium acetate. This was followed by precipitation of the sodium salt using
~10 volumes of cold ethanol. The precipitated product was further purified using
Millipore filter (NMWC 3-30 kDa) at 4000 g.

2.3.5 Structural characterization
2.3.5.1 Determination of molecular weight of sulfated and unsulfated DHP fractions
The number and weight average molecular weight of unsulfated DHP fractions was
measured using gel permeation chromatography (GPC). Size exclusion chromatography
(SEC) was employed in case of sulfated DHP fractions for determination of peak average
molecular weight. In both cases the system was composed of LC10Ai pumps and a SPD10A VP UV-vis detector controlled by a SCL-10A VP system controller connected to a
computer. For SEC each fraction was analyzed using Asahipak GS320 HQ column with
an isocratic flow rate of 0.7 mL/min of 0.1 N NaOH at pH 11.0. Polystyrene sulfonate
standards (PSS) were used for calibration purposes. For GPC each fraction was analyzed
using Phenogel 5 μ (Phenomenex, Torrance, CA, 7.6 mm i.d. x 300 mm). The mobile
phase consisted of 100% tetrahydrofuran at a constant flow rate of 0.7 mL/min.
Polystyrene standards (PS) were used for calibration purposes. The relationship between
logarithm of the molecular weight and the elution volume (V) of the standards was found
to be linear with a correlation coefficient of 0.98 and 0.99. The wavelength of detection
for CD and FD fractions was set at 280 nm. Each chromatogram was sliced into 1000
time periods providing 1000 MR with the corresponding absorbance (A) values. These
values were used to calculate number average molecular weight (MN), weight average
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molecular weight (MW) and polydispersity (P) parameters from equations 1, 2, and 3,
respectively, for each fraction.

MN =

∑ Ai × Mi
∑ Ai

∑ Ai × Mi2
MW =
∑ Ai × Mi

…… (1)

P=

MW
MN

…… (2)

…… (3)

2.3.5.2 Elemental analysis
Elemental Analysis of DHP samples was obtained from Atlantic Microlabs (Norcross,
GA).

2.3.5.3 NMR
1

H- and 13C- NMR spectra were recorded with a Bruker AVANCE II 400 FT-NMR (400

MHz) spectrometer in water-d and DMSO-d for sulfated and unsulfated fractions with
tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) are reported in δvalues (ppm).

2.3.6 Prothrombin time and activated partial thromboplastin time
Clotting time was determined in a standard 1-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD). For PT and APTT assays, the
reagents were pre-warmed to 37 °C. For PT assays, 10 μL of the anticoagulant (or the
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reference molecule) was mixed with 90 μL of citrated human plasma, incubated for 30 s
at 37 °C quickly followed by addition of 200 μL pre-warmed thromboplastin. For APTT
assays, 10 μL of the anticoagulant was mixed with 90 μL citrated human plasma and 100
μL 0.2% ellagic acid. After incubation for 240 s, clotting was initiated by quickly adding
100 μL of 25 mM CaCl2. Each experiment was performed in duplicate. The averaged
data was fitted using a quadratic equation to calculate the concentration of the
anticoagulant necessary to double the clotting time (2 × PT or 2 × APTT).

2.3.7 Proteinase inhibition
Direct inhibition of thrombin and fXa by sulfated and unsulfated DHP fractions was
determined through a chromogenic substrate hydrolysis assay. For these assays, a 10 μL
DHP fraction at several different concentrations was diluted with appropriate buffer
system in a PEG 20,000 coated polystyrene cuvettes. This was followed by addition of
the 5µL of proteinase, thrombin (960nM) or fXa (1µM) and incubated at 37°C for 10
minutes. Following incubation, 10µL of spectrozyme TH (2mM) or spectrozyme fXa
(5mM) was rapidly added and the residual thrombin activity was quantified by measuring
the initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a
function of time under conditions wherein less than 10% substrate is consumed. Relative
residual proteinase activity at each activity measured under otherwise identical
conditions, except for the absence of the inhibitor. Logistic equation 4 was used to fit the
dose dependence of residual proteinase activity to obtain IC50.

Y = YO +

YM − YO

1 + 10(log[L]O − log IC50) × HC
35

…... (4)

In this equation Y is the ratio of residual thrombin activity in the presence of the inhibitor
to that in its absence; YM and Y0 are the maximum and minimum possible values of the
fractional residual thrombin activity, respectively; IC50 is the concentration of the
inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill slope. HS
does not represent co-operativity because the sulfated and unsulfated DHP fractions are a
highly complex species that may possess multiple binding modes and geometries.
Sigmaplot 9.0 (SPSS, Inc. Chicago, IL) was used to perform non-linear curve fitting in
which YM, YO, IC50 and HS were allowed to float.

2.3.8 Mechanistic studies
2.3.8.1 Michaelis-Menten kinetics
Several concentrations of Spectrozyme TH (0.25 to 25 μM) were treated with 4 nM
thrombin in presence of fixed concentration of inhibitor (0 - 5 μg/mL). The initial rate of
substrate hydrolysis was monitored from the linear increase in A405 in 20 mM Tris-HCl
buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 at 25 °C.
The data obtained was fitted by the standard Michaelis-Menten equation to calculate that
apparent KM and VMAX.

2.3.8.2 Competitive binding studies with exosite ligands [5F]-Hir[54-65](SO3-) or
porcine heparin
Inhibitor-dependent thrombin inhibition studies in the presence of [5F]-Hir[54-65](SO3-)
or porcine heparin were performed in a manner similar to that described above using the
chromogenic substrate hydrolysis assay. Briefly, a solution of inhibitor over several
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different concentrations and thrombin (4nM) was incubated for 10 minutes at 37°C with
either [5F]-Hir[54-65](SO3-) (0 and 86 nM) or porcine heparin (0, 20 and 100 M) in 20 mM
Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000.

Following incubation, Spectrozyme TH was added to yield a final concentration of 20µM
and its hydrolysis was measured as the initial change in absorbance at 405. The molecular
weight of bovine heparin was assumed to be 15000, as reported in the literature. The
dose-dependence of the fractional residual proteinase activity at each concentration of the
competitor was fitted by equation 04 to obtain the apparent concentration of inhibitor
required to reduce thrombin activity to 50% of its initial value (IC50,app).

2.3.9 Cellular toxicity studies
The alamar blue assay was performed with a fluorimetric method using HepG cells in a
96-well plate. The wells contained 100 µL of medium containing cells to which 10 µL of
alamar blue was added and incubated for 4 hours at 37°C. The plates were exposed to an
excitation wavelength of 531 nm and the emission at 590 nm was recorded on a Perkin
Elmer fluorimeter. The percent viability was expressed as fluorescence emitted by treated
cells compared to control (medium or vehicle only).
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2.4

Results

2.4.1 Synthesis of unsulfated and sulfated DHPs and its fractions
Based on our earlier reports from our work we know that sulfated DHPs of CA (CDS)
and FA (FDS) were potent dual inhibitors of thrombin and fXa. Both are a heterogeneous
and complex mixture of molecules containing variety of chain lengths and linkages
posing a hindrance in identification of the effector molecule. To identify the optimum
chain length, which can be further optimized we decided to synthesize them on large
scale. Both CD and FD were synthesized from their respective starting monomers using
oxidative coupling reaction using an enzyme, HRP (figure 14). This reaction generates
free radical intermediates, which reacts with monomers to form a coupled product. This
reaction persists until stopped to form longer oligomers and possibly variable linkages at
the point of attachment. β-O-4 and β-5 type of linkages are easily feasible with this type
of reaction as also seen in natural lignins which contain high amount of these linkagetypes in addition to others.
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Figure 14. Chemo-enzymatic synthesis of 4-hydroxycinnamic acid-based dehydropolymers
(DHPs), CD and FD.
Horseradish peroxidase (HRP)-catalyzed oxidative coupling of caffeic acid (CA) or ferulic acid
(FA) in the presence of H2O2 generates oligomers of size 3–34 U. Phenolic oxidation generating
radical intermediates I1 and I2 couple with starting material to give oligomers with different types
of inter-monomeric linkages. The most common linkages formed include β-O-4 and β-5.124

A part of these DHP samples synthesized enzymatically were subjected to different size
MWCO filters (30kDa to 3kDa) where they were fractionated based on their molecular
size (figure 15). In all, five samples of each DHP were obtained from this exercise. The
samples that passed through the MWCO filter 3kDa were discarded as it would contain
high amount of salt and unreacted starting material, if any.
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DHP mixture

30K

10K

5K

3K

Figure 15. Fractionation of CD and FD using MWCO filters ranging from 30 – 3 kDa

Further 50mg of all 10 samples were subjected to sulfation to yield the sulfated counter
part of each DHP. DHPs were sulfated using TEAST complex under conditions
established earlier in our lab and a brief description can be found in the methods section.
In this reaction the free hydroxyl and the free phenolic groups are sulfated (figure 16).
Introduction of sulfate groups impart a greater anionic character to the DHPs.

Figure 16. Sulfation of CD and FD using triethylamine sulfur-trioxide complex
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2.4.2 Molecular weight and size determination
To determine molecular weight of the sulfated and unsulfated DHPs and its fraction SEC
and GPC respectively were employed. PS and PSS standards were used for GPC and
SEC methods respectively (figure 17). In both cases DHPs of FA were found to be larger
in size, generating longer chains. The peak average molecular weight (MP) of unsulfated
CD fractions ranged from 900 to 2210 while for FD fractions it was found to be 750 to
7700. The MP of sulfated CD fractions ranged form 950 to 2890 while for sulfated FD
fractions it was less than 1550 to 9780. Chain lengths were calculated by dividing the MP
by the molecular weight of the starting monomer, which was in turn back calculated from
the standard curve, obtained using PS. The molecular weight of the CA and FA were
determined to be 262 and 226 respectively. The average peak chain length for CD
fractions using PS standards ranged from 3.4 to 8.4 whereas, for FD oligomers it was
found to range from 3.3 to 24.0 (Table 01). This implies the wider chain distribution
pattern for FD fractions (7.3-fold) and CA (2.5-fold). The apparent molecular weight
calculated for sulfated fractions using SEC were found to be the lowest for 3CDS (950)
and highest for 30FDS (9780). Further, the difference in the molecular weights of the
sulfated and the unsulfated DHPs obtained by SEC and GPC gives an apparent molecular
weight of the total number of sulfates that might be present. Using the difference and
dividing it by the chain length we can calculate the apparent number sulfates groups on
DHPs (Table 02). The apparent average number of sulfates for all CD fractions was
determined to be 3 sulfates per dimer with the exception of 3CD having 0.2 sulfate per
monomer. A similar calculation for FD fractions revealed an average of 1 sulfate per
dimer for all fractions. The average number of sulfates for the parent mixture of DHPs of
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both CA and FA were 1 and 0.5 sulfate per monomer. Overall, this indicates that CD
fractions are smaller in size (~3-fold) and more sulfated (2-3-fold) than the FD fractions,
overall imparting a more anionic character to them. The MN values for the unsulfated CD
and FD fractions ranged from 1052 to 7558, while MW was found to be in the range of
2084 and 16464. This when compared with MP values indicate the presence of greater
number of smaller chains in the mixture. Refer Table 01 below for all the molecular
weight characteristics for each fraction of the unsulfated DHPs and their chain lengths.

Table 01: Molecualr weight characterization of CD and FD fractions

MNa

MWa

MPa

Pb

LRc

FD3

(Da)
1270

(Da)
5299

(Da)
750

4.2

3.3 (1-25)c

FD5

2750

9690

1300

3.5

5.7 (1-44)

FD10

4997

13209

2650

2.6

11.7 (1-58)

FD30

7558

16464

7700

2.2

34.0 (1-72)

FDMIX

5322

11525

5440

2.2

24.0 (1-49)

CD3

1052

2084

900

2.0

3.4 (1-9)

CD5

1629

6927

1100

4.3

4.2 (1-28)

CD10

2484

8588

1470

3.5

5.6 (1-46)

CD30

3937

12788

1980

3.2

7.6 (1-50)

CDMIX

4264

13272

2210

3.1

8.4 (1-51)

a

Number, weight, and peak average molecular weights were obtained by GPC analysis.
Polydispersity. cThe peak average chain length was calculated from the ratio of MP and
molecular weight of the two monomers calculated using PS standard curve. Numbers in brackets
refer to the range of chain lengths (see Experimental Methods).
b
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Table 02: aPeak average molecular weights obtained by GPC analysis (see Experimental
Methods).

MP S
(Da)
FA
CA
03FD
05FD
10FD
30FD
FD
03CD
05CD
10CD
30CD
CD

1550
3170
9780
6350
950
1690
2200
2880
2890

MP US MP (S-US)
(Da)
(Da)
a
226.4
262.1a
750
1300
250
2650
520
7700
2080
5440
910
900
50
1100
590
1470
730
1980
900
2210
680

ST

LR

S/unit

3.1
6.5
26.0
11.4
0.6
7.4
9.1
11.3
8.5

3.3
5.7
11.7
34.0
24.0
3.4
4.2
5.6
7.6
8.4

0.54
0.56
0.76
0.47
0.18
1.76
1.63
1.49
1.01

MP S refers to peak average molecular weight of sulfated fractions obtained by SEC analysis.
MP US refers to peak average molecular weight of unsulfated fractions obtained by GPC analysis.
MP (S-US) refers to peak average molecular weight of sulfate(s) obtained by subtracting
unsulfated fractions from the sulfated ones.
ST refers to total number of sulfates present obtained by dividing peak average molecular weight
of sulfate(s) by calculated molecular weight of sulfate.
LR refers to peak average chain length calculated from the ratio of MP and molecular weight of the
two monomers calculated using PS standard curve.
S/unit refers to apparent number of sulfates calculated from the ratio of total number of sulfates
(ST) and peak average chain length (LR).
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Figure 17. GPC and SEC of CD and FD fractions using PS and PSS as standards,
respectively.
A) & B) represent the linear curve obtained using PS (using GPC) and PSS (using SEC),
respectively. A1) & A2) are the chromatograms acquired using GPC for CD and FD fractions,
respectively. A2) and B2) are the chromatograms acquired using SEC for CDS and FDS fractions,
respectively.

44

2.4.3 Elemental analysis
To assess the level of sulfation elemental analysis was carried out to determine the
composition of each element. Average chain length determined by GPC was used to
calculate the theoretical number of sulfates for all samples. The number of sulfates for
CDS30, CDS10, FDS30 and FDS10 using elemental analysis were found to be 0.38,
0.33, 0.2 and 0.16 per monomer which were fairly similar compared to the theoretical
numbers (Table 03). The difference arises due to the heterogeneous nature of the samples
making it extremely difficult to assign an exact size or composition. There is a ~2-fold
difference in the level of sulfation between each group, CDS30-FDS30 and CDS10FDS10.

Table 03: Elemental Analysis of sulfated fractions of DHP

C (%)

H (%)

O (%)

S (%)

S/unit

30CDS

44.9 (51.1)a 3.1 (3.7) 37.1 (39.1) 5.8 (5.7)

0.38

30FDS

52.7 (56.1)

4.4 (4.4) 34.7 (36.3) 3.2 (3.2)

0.20

10CDS

46.1 (52.3)

3.5 (3.7) 35.6 (38.7) 5.1 (5.2)

0.33

10FDS

48.4 (57.0)

4.4 (4.4) 36.4 (35.9) 3.0 (2.7)

0.16

05CDS

49.0 (54.1)

3.2 (3.9) 35.0 (38.0) 3.6 (4.0)

0.25

Number in brackets show the predicted composition of a homogenous β-O-4-linked oligomer of
appropriate sulfated DHP fraction. The peak average chain length was used in these calculations
are represented in Table 02.
S/unit refers to average number of sulfates per monomeric unit, which was calculated from
elemental sulfur composition and the size of an average unsulfated oligomer.
a
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2.4.4 NMR
The 1H NMR spectra of parent DHPs showed the presence of broad peaks (not shown),
which on fractionation to lower molecular weight did not resolve enough for structural
assignments (figure 18A) indicative of a polydisperse nature. The quantitative 13C NMR
like the 1H was only indicative of the functional group type present in the DHP mixture
(figure 18B).

A)

B)

Figure 18. A) 1H NMR spectra of FD and B) quantitative 13C NMR spectra of CD both in
DMSO-d6.
Four regions are apparent in both the spectra, the carboxylic acid region between 10-11ppm in 1H
or 160-170 ppm in 13C, the aromatic and vinylic peaks between 6-8ppm in 1H or 100-160 ppm in
13
C, the α and β-carbons of alkoxy groups between 5-5.2 ppm in 1H or 70-80 ppm in 13C, and the
methoxyl groups at 3.8ppm in 1H or 56 ppm in 13C. Solvent signal is observed at 2.5 ppm in 1H or
40 ppm in 13C.
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2.4.5 Plasma clotting assays
Prothrombin and activated partial thromboplastin time (PT and APTT) are reflective of
the activity of the extrinsic and intrinsic pathways of coagulation. Both are commonly
used to assess the coagulation status of human plasma. APTT and PT were measured in
duplicate or triplicate over a range 10-12 different concentrations of sulfated and
unsulfated DHP fractions. Water was used as blank and enoxaparin was used as a
reference indicator. All fractions exhibited a significant concentration-dependent
prolongation of PT and APTT. The anticoagulant activity is a measure of the amount of
anticoagulant required to double the clotting time (2 x APTT or 2 x PT). The amount of
sulfated and unsulfated CD fractions required to achieve the doubling of plasma clotting
time ranged from 18 (6.3 µM) to 200 µg/mL (222.2 µM) and 51 (17.7 µM) to 682 µg/mL
(757.8 µM) for APTT and PT respectively (figure 19a & b). Likewise, concentrations
ranging from 30 to 203 µg/mL (3.0 to 270.7 µM) and 74 to 248 µg/mL (7.6 to 597.3 µM)
of sulfated and unsulfated FD fractions were required in the APTT and PT assays
respectively (figure 19c & d), refer Table 04. This indicated that our samples were more
potent anticoagulant (1.8-3.4-fold) in acting through the intrinsic pathway. In contrast,
enoxaparin brought about 2 x APTT at 5.4 µg/mL (1.2 µM) and 2 x PT at 338.9 µg/mL
(75.3 µM). This imply that our samples were at least 2.5-fold weaker in the APTT assay
and at most 9.9-fold more potent in the PT assay. Also, there is a clear trend with the
longer chains in both CD and FD being more potent than the smaller ones. When sulfate
and unsulfated CD and FD fractions are compared side by side there is no significant
difference except for 30CDS and 30CD being 3.6 and 2.1-fold more active, which is still
not enormous.
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Figure 19: Plasma clotting assay for both unsulfated and sulfated CD and FD fractions
a) & b) figures represent APTT and PT results for CD and CDS fractions
c) & d) figures represent APTT and PT results for FD and FDS fractions

48

300

Table 04: Anticoagulation effect of DHP fractions on plasma

APTT
CDS
CD
30CDS
30CD
10CDS
10CD
05CDS
05CD
03CDS
03CD
FDS
FD
30FDS
30FD
10FDS
10FD
05FDS
05FD
03FDS
03FD

(μg/ml)
23 ± 1.8
36 ± 1.8
18 ± 1.3
49 ± 1.5
57 ± 1.1
72 ± 3.6
109 ± 3.3
130 ± 7.8
160 ± 16
200 ± 16
36 ± 1.1
66 ± 1.3
29.5 ± 1.2
53 ± 3.2
72 ± 3.6
99 ± 4.0
144 ± 10.1
165 ± 13.2
nd
203 ± 22.3

PT

(μM)
8 ± 0.6
16.3 ± 0.8
6.3 ± 0.4
24.8 ± 0.7
25.9 ± 0.5
49 ± 2.5
64.5 ± 1.9
118.2 ± 7.1
168.4 ± 16.8
222.2 ± 17.8
5.7 ± 0.2
12.1 ± 0.2
3.0 ± 0.1
6.9 ± 0.4
22.7 ± 1.1
37.4 ± 1.5
92.9 ± 6.5
126.9 ± 10.2
nd
270.7 ± 29.7

(μg/ml)
63 ± 5.0
125 ± 6.3
51 ± 3.6
119 ± 3.6
166 ± 3.3
191 ± 9.6
272 ± 8.2
385 ± 23.1
542 ± 54.2
682 ± 54.6
98 ± 2.9
182 ± 3.6
74 ± 3.0
132 ± 7.9
198 ± 9.9
287 ± 11.5
265 ± 18.6
290 ± 23.2
nd
448 ± 49.3

(μM)
21.8 ± 1.7
56.6 ± 2.8
17.7 ± 1.2
60.1 ± 1.8
75.5 ± 1.5
129.9 ± 6.5
161 ± 4.8
350 ± 21
570.5 ± 57.0
757.8 ± 60.6
15.4 ± 0.5
33.5 ± 0.7
7.6 ± 0.3
17.1 ± 1.0
62.5 ± 3.1
108.3 ± 4.3
171 ± 12.0
223.1 ± 17.9
nd
597.3 ± 65.7

PT and APTT values were deduced in in vitro human plasma experiments where the clot initiator
is either thromboplastin or ellagic acid,respectively. Experiments were performed in duplicate or
triplicate. Errors represent ±1 SE.
nd – Not determined

2.4.6 Direct Inhibition of Coagulation Proteinases
It is evident by the APTT and PT assays that all DHP fractions are able to double the
plasma clotting time. This signifies that most likely it is acting through the common
pathway in the coagulation cascade. The two key proteinases in the common pathway
being thrombin and fXa we chose to investigate if our DHP fractions indeed affect their
proteolytic activities. Enzyme inhibition studies were performed where the substrate

49

hydrolysis was measured in presence of a range of inhibitor concentrations. The substrate
hydrolysis decreased in sigmoidal fashion with the increase in concentration of the
inhibitors. A standard dose-dependent equation was used to fit the curve and derive IC50
values.

The unsulfated and sulfated DHP fraction showed dual inhibition by inhibiting both
thrombin and fXa. The IC50 values of unsulfated FD and CD fractions were found to be
from 855 to 8610 ng/mL (0.111-11.5 µM) and 231 to 3360 ng/mL (0.117-3.7 µM) in case
of thrombin (figure 20 a-b), whereas for fXa it ranged from 1730 to 11143 ng/mL
(0.225-14.9 µM) and 263 to 8240 ng/mL (0.133-9.2 µM) respectively (figure 20 c-d).
Likewise, IC50 values of sulfated FD and CD fractions vary 508 to 2320 ng/mL (0.0521.5 µM) and 91.6 to 2840 ng/mL (0.032-2.9 µM) for thrombin (figure 20 a-b); similarly
for fXa inhibition the values were 1090 to 4990 ng/mL (0.112-3.2 µM) and 132 to 3750
ng/mL (0.046-3.9 µM) (figure 20 c-d). See Table 05 and 06 for inhibition related data of
all fractions. This suggests few notable features of our fractionated DHPs. First, the
inhibition pattern for both the proteases clearly shows chain length dependence; where
longer chains are more active most probably due to better interactions with the large
binding sites on thrombin and fXa. Secondly, in concurrence with the parent DHP
mixture the fraction as expected inhibit thrombin better than fXa (up to 2.9-fold weaker).
Lastly, the most striking observation is the difference in inhibition between the sulfated
and unsulfated species. The sulfated DHP fractions are better inhibitors of both the
proteases as compared to its unsulfated counterpart (up to 3.7-fold). This is not a huge
difference considering the fact that these samples are being used for development of
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better drugs through structure-based drug design. Lastly, the unsulfated possess less
anionic character making it better suitable for further development as it reduces the
possibility
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Figure 20. Inhibition of blood coagulation proteases, thrombin (a&b) and fXa (c&d) by sulfated
and unsulfated DHP fractions
a) & b) represent the sigmoidal inhibition profile of thrombin by sulfated and unsulfated CD and FD
fractions
c) & d) represent the sigmoidal inhibition profile of fXa by sulfated and unsulfated CD and FD fractions
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Table 05: Inihibition of thrombin by sulfated and unsulfated DHP fractions

YO

YM

HS

IC50 (μg/ml)

IC50 (nM)

CDS
CD
30CDS
30CD
10CDS
10CD
05CDS
05CD
03CDS
03CD

log IC50
(mg/ml)
-3.97 ± 0.04
-3.59 ± 0.03
-4.04 ± 0.05
-3.64 ± 0.03
-3.79 ± 0.04
-3.41 ± 0.02
-3.38 ± 0.03
-3.25 ± 0.03
-2.55 ± 0.04
-2.47 ± 0.07

21.4 ± 1.7
20.8 ± 1.4
21.6 ± 2.0
22.1 ± 1.3
28.3 ± 1.8
24.0 ± 0.8
20.3 ± 1.7
25.9 ± 1.8
21.8 ± 2.1
21.4 ± 3.9

103 ± 2.0
102 ± 1.8
104 ± 2.6
101 ± 1.5
103 ± 1.7
100 ± 0.7
100 ± 1.5
103 ± 1.4
105 ± 2.5
106 ± 3.5

1.0 ± 0.1
1.0 ± 0.1
1.0 ± 0.1
1.1 ± 0.1
1.3 ± 0.1
1.3 ± 0.1
1.1 ± 0.1
1.5 ± 0.1
1.1 ± 0.1
1.0 ± 0.2

0.108 ± 0.01
0.258 ± 0.02
0.092 ± 0.01
0.231 ± 0.02
0.163 ± 0.01
0.391 ± 0.01
0.420 ± 0.03
0.568 ± 0.04
2.840 ± 0.28
3.360 ± 0.50

37.4 ± 3.5
116.7 ± 9.1
31.8 ± 3.5
116.7 ± 5.1
74.1 ± 5.0
266.0 ± 7.0
248.5 ± 18.0
516.4 ± 36.0
2989 ± 295
3733 ± 555

FDS
FD
30FDS
30FD
10FDS
10FD
05FDS
05FD
03FDS
03FD

-2.98 ± 0.05
-2.69 ± 0.01
-3.29 ± 0.03
-3.07 ± 0.03
-2.94 ± 0.04
-2.70 ± 0.01
-2.64 ± 0.05
-2.50 ± 0.03
nd
-2.07 ± 0.05

17.6 ± 2.3
22.4 ± 0.5
26.5 ± 1.3
21.8 ± 1.4
19.2 ± 2.4
23.2 ± 0.5
21.5 ± 1.9
26.4 ± 1.3
nd
28.8 ± 4.3

102 ± 1.1
101 ± 0.8
101 ± 1.4
103 ± 1.9
102 ± 1.4
102 ± 0.8
101 ± 2.7
101 ± 1.5
nd
103 ± 1.9

0.7 ± 0.1
1.6 ± 0.1
1.3 ± 0.1
1.0 ± 0.1
0.9 ± 0.1
1.2 ± 0.1
1.0 ± 0.1
1.3 ± 0.1
nd
1.5 ± 0.2

1.050 ± 0.11
92.6 ± 9.0
2.060 ± 0.06 264.7 ± 20.2
0.508 ± 0.03
51.9 ± 3.1
0.855 ± 0.06 111.0 ± 7.8
1.150 ± 0.10 362.8 ± 31.5
2.020 ± 0.06 762.3 ± 22.6
2.320 ± 0.02 1497 ± 12.9
3.160 ± 0.20 2431 ± 154
nd
nd
8.610 ± 0.90 11480 ± 1200

Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM
NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes.
Spectrozyme TH was used as substrate and the residual enzyme activity in the presence of
inhibitor was assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic
equation 4 was used to fit the dose dependence of the residual enzyme activity to obtain log
IC50, Y0, YM and HS values. See Methods for details.
Errors represent ±1 SE
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Table 06: Inihibition of fXa by sulfated and unsulfated DHP fractions

YO

YM

HS

IC50 (μg/ml)

IC50 (nM)

CDS
CD
30CDS
30CD
10CDS
10CD
05CDS
05CD
03CDS
03CD

log IC50
(mg/ml)
-3.77 ± 0.06
-3.43 ± 0.03
-3.88 ± 0.05
-3.58 ± 0.09
-3.41 ± 0.06
-3.10 ± 0.08
-2.95 ± 0.06
-2.78 ± 0.04
-2.43± 0.20
-2.08 ± 0.02

1.66 ± 4.4
12.2 ± 1.9
21.5 ± 2.6
16.5 ± 4.9
17.4 ± 3.8
17.7 ± 5.3
19.2 ± 3.5
14.0 ± 2.1
15.4 ± 1.3
18.0 ± 0.9

110 ± 3.6
105 ± 1.8
105 ± 2.7
112 ± 6.3
99 ± 1.9
102 ± 2.7
99 ± 2.1
100 ± 1.3
105 ± 3.4
103 ± 1.0

0.6 ± 0.1
0.8 ± 0.1
1.0 ± 0.1
0.7 ± 0.1
1.0 ± 0.1
0.9 ± 0.1
1.1 ± 0.2
1.0 ± 0.1
0.6 ± 0.1
1.1 ± 0.1

0.171 ± 0.02
0.368 ± 0.03
0.132 ± 0.02
0.263 ± 0.05
0.390 ± 0.05
0.804 ± 0.14
1.110 ± 0.14
1.650 ± 0.14
3.750 ± 1.69
8.240 ± 0.39

59.2 ± 6.9
166.5 ± 9.1
45.8± 3.5
132.8 ± 5.1
177.3 ± 5.0
546.9 ± 7.0
650.9 ± 18.0
1500 ± 36.0
3947 ± 1800
9156 ± 433

FDS
FD
30FDS
30FD
10FDS
10FD
05FDS
05FD
03FDS
03FD

-3.23 ± 0.02
-2.84 ± 0.03
-2.96 ± 0.06
-2.76 ± 0.02
-2.62 ± 0.03
-2.53 ± 0.04
-2.30 ± 0.02
-2.19 ± 0.05
nd
-1.95 ± 0.02

30.9 ± 0.8
22.9 ± 1.4
22.4 ± 3.6
22.0 ± 1.1
11.6 ± 1.9
18.2 ± 2.1
24.1 ± 0.8
14.6 ± 3.8
nd
16.5 ± 0.9

101 ± 0.8
102 ± 1.7
102 ± 2.2
100 ± 1.0
102 ± 1.3
104 ± 2.5
102 ± 1.0
105 ± 2.5
nd
103 ± 0.9

1.7 ± 0.1
1.1 ± 0.1
0.9 ± 0.1
1.2 ± 0.1
0.8 ± 0.1
1.0 ± 0.1
1.1 ± 0.1
0.9 ± 0.1
nd
1.0 ± 0.1

0.588 ± 0.06 164.9 ± 9.0
1.440 ± 0.11 377.9 ± 20.2
1.090 ± 0.15 111.5 ± 3.1
1.730 ± 0.09 224.7 ± 7.8
2.380 ± 0.18 750.8 ± 31.5
2.960 ± 0.28 1117 ± 22.6
4.990 ± 0.24 3219 ± 12.9
6.530 ± 0.82 5023 ± 154
nd
nd
11.10 ± 0.44 14857 ± 1200

Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM
NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes.
Spectrozyme fXa was used as substrate and the residual enzyme activity in the presence of
inhibitor was assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic
equation 4 was used to fit the dose dependence of the residual enzyme activity to obtain log
IC50, Y0, YM and HS values. See Methods for details.
Errors represent ±1 SE
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2.4.7 Identifying the binding site of CD10 and FD10
Based on the known mechanism of FDS and CDS mixtures we expected the fraction to
behave the same way by acting through the exosite-2 on thrombin. We chose to work
with an intermediate active fraction as the yields of the larger fractions were much higher
after fractionation. This implies that the mixture possesses its activity mainly because of
the larger fractions as evident by protease inhibition studies. To ascertain that indeed this
was true we performed a quick study with one of the fractions from each and not
surprisingly found the mechanism to be the same. Michaelis Menten kinetic studies with
CD10 and FD10 were performed (figure 21a & b) to probe if the inhibitors were acting
through binding at the active site. The KM was found to be steady between 1.2 – 1.8 µM
and the VMAX steadily decreased from 24 – 11 mAbsU/min in presence of increasing
concentration of the inhibitor (20 – 5000 ng/mL). The catalytic efficiency of the reaction
steadily decreased from ~45 to ~18 s-1, refer Table 07. These signify that there is no
effect on substrate binding to the active site to form the thrombin–Spectrozyme TH
Michaelis complex but the conversion of the complex to the final product is definitely
retarded. To further ascertain that the fractions like the parent DHPs bind in the exosite-2
of thrombin, competitive binding studies in presence [5F]-Hir[54-65](SO3-), an exosite-1
binding ligand (figure 22a & b) and heparin, an exosite-2 binding ligand (figure 23a &
b) was performed. Based on previous studies we chose to screen exosite-1 ligand at a
concentration of 86nM (3 x KD) and heparin at 20 µM (1 x KD) and 100 µM (5 x KD).
These studies revealed that our fractions indeed bind in the exosite-2 of thrombin as
IC50,app changed significantly from 210 nM to 946 nM and 600 nM to 7.3 µM for CD10
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and FD10, respectively in presence of increasing concentration of exosite-2 competitor,

Initial rate of hydrolysis
mAU/min

whereas it remained unchanged in presence of exosite-1 competitor (Table 08).
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Figure 21a & b: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in
the presence of DHP fractions.
Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by thrombin in the presence of 10CD
(figure 20a) and 10FD (figure 20b).
The initial rate of hydrolysis at various substrate concentrations was measured in pH 7.4 buffer as
described in ‘Experimental Procedures’. Solid lines represent non-linear regressional fits
to the data using the Michaelis-Menten equation.
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Table 07: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in the
presence of inhibitors

[10CD]o

Km

Vmax

kcat

(ng/mL)

(µM)

(mAbsU/min)

(s -1)

0
20
100
400
1000
[10FD]o
0
100
500
2000
5000

2.3 ± 0.1
1.4 ± 0.2
1.2 ± 0.1
1.2 ± 0.2
1.8 ± 0.3

27.0 ± 0.4
21.8 ± 0.7
18.8 ± 0.4
13.2 ± 0.3
11.2 ± 0.4

45.4 ± 0.7
36.6 ± 1.2
31.6 ± 0.7
22.2 ± 0.5
18.8 ± 0.7

2.3 ± 0.1
1.2 ± 0.2
1.4 ± 0.2
1.3 ± 0.3
1.3 ± 0.2

27.0 ± 0.4
23.8 ± 0.7
20.5 ± 0.5
14.6 ± 0.7
11.0 ± 0.3

45.4 ± 0.7
40.0 ± 1.2
34.4 ± 0.8
24.5 ± 1.2
18.5 ± 0.5

a

KM and VMAX were measured as described in ‘Experimental Procedures’.
Error represents 1 S.E.

b
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Figure 22. Inhibition of thrombin by DHP in presence of exosite-1 ligand
Competitive effect of [5F]-Hir[54-65](SO3-) on the inhibition of thrombin by 10CD (figure 21a)
and 10FD (figure 21b). Residual thrombin activity was measured through Spectrozyme TH
hydrolysis in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 %
polyethylene glycol (PEG) 8000 at 37 OC in the presence of 0 and 86 nM [5F]-Hir[54-65](SO3-).
Solid lines represent fits using the logistic equation 4 to obtain the apparent IC50, as described in
‘Experimental Procedures’.
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Figure 23. Inhibition of thrombin by DHP in presence of exosite-2 ligand
Competitive effect of porcine heparin on the inhibition of thrombin by 10CD (figure 22a) and
10FD (figure 22b). Residual thrombin activity was measured through Spectrozyme TH hydrolysis
in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 %
polyethylene glycol (PEG) 8000 at 37 OC in the presence of 0, 20 and 100 μM porcine heparin.
Solid lines represent fits using the logistic equation 4 to obtain the apparent IC50, as described in
‘Experimental Procedures’.
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Table 08: Inhibition of thrombin by 10CD and 10FD in the presence of hirugen analog [5F]Hir[54-65](SO3-) and porcine heparin a
[Competitor]
[10CD]
[10FD]

[10CD]
[10FD]

log IC50
(mg/ml)

Hirugen Analog
0nM
-3.51 ± 0.3
86nM
-3.41 ± 0.02
0nM
-2.80 ±0.02
86nM
-2.70 ± 0.08
Porcine Heparin
20μM
-3.16 ± 0.02
100μM
-2.86 ± 0.02
20μM
-2.16 ± 0.06
100μM
-1.72 ± 0.06

Y0

YM

HS

IC50 (µg/ml)

IC50 (nM)

25.8 ± 1.2
20.4 ± 0.9
23.1 ± 0.6
21.2 ± 3.5

99.2 ± 1.2
101 ± 0.8
102 ± 0.9
106 ± 4.8

1.4 ± 0.1
1.5 ± 0.1
1.2 ± 0.1
1.1 ± 0.2

0.31 ± 0.02
0.39 ± 0.01
1.59 ± 0.05
1.98 ± 0.30

211 ± 13.6
265 ± 6.80
600 ± 18.9
747 ± 113

27.5 ± 1.2
36.7 ± 0.9
21.0 ± 3.0
29.9 ± 2.7

99.8 ± 1.0
100 ± 0.4
102 ± 2.1
101 ± 1.5

1.5 ± 0.1
1.0 ± 0.1
0.8 ± 0.1
0.9 ± 0.1

0.70 ± 0.04
1.39 ± 0.06
6.95 ± 0.90
19.3 ± 2.60

476 ± 27.2
945 ± 40.8
2600 ± 340
7300 ± 981

a

Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl,
2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvette. Spectrozyme TH
was used as substrates and the residual enzyme activity in the presence of FDSO3 was assessed
by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic equation I was used to fit
the dose dependence of the residual enzyme activity to obtain log IC50, Y0, YM and HS values.
See Methods for details.
b
represents 1 ±S.E.

2.4.8 Cellular toxicity studies
The alamar blue assay functions on the ability of viable cells to reduce alamar blue
(resazurin) to resofurin (highly red fluorescent), which can be quantified using
fluorimeteric methods. All fractions screened for cytoxicity were found to be non-toxic
with more than 80% cell viability at concentration as high as 500 µg/mL (figure 24).
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Figure 24. Toxicity studies on the unsulfated CD and FD fractions
The alamar blue assay was performed with a fluorimetric method using HepG cells. All fractions
of both CD and FD were able to sustain cell viability at concentrations as high as 500 μg/ml.

2.5

Discussion

In an attempt to mimic structural features of heparin by replacing the carbohydrate
backbone with an aromatic scaffold and also contain structural intricacy similar to that of
heparin we chose to work with lignins containing the carboxylate functionality. However,
natural lignins do not contain carboxylic acid groups. So, what does lignin have to offer?
It is a complex and heterogenous polymer just like heparin. It has a rigid aromatic
backbone with flexibility introduced at the point of attachment of each monomer, a
property lacked by heparin. The aromatic skeleton might impart structural specificity due
to its hydrophobic nature and restrained conformation. Lignins contain diverse type of
linkages and the molecular weight is close to 5000 a property shared with LMWH.
Lignins have free –OH groups, which could potentially make H-bonding or could be
derivatized to yield its sulfated form. In terms of synthesis these are easy to synthesize
even on bulk scale, which is not the case with heparins. Finally, lignins offer an avenue to
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potentially discover sequence(s) similar to that of the potent pentasaccharide sequence in
heparin.

We utilized HRP-catalyzed oxidative coupling conditions, such as high reactant
concentrations and controlled gradual addition of the oxidant, which reduce chain
termination, to obtain oligomers with peak average molecular weight between 750-7700.
This corresponds to a very diverse chain length numbers ranging from a trimer up to 24mer. The GPC profiles obtained were broad and reasonably symmetrical implying that
each fraction contained nearly all types of chains. For example, although the average
chain length of FD3 and CD3 is 3.4 and 3.3, both fractions contain chains as long as 24
and 8 units, respectively. This indicates that each type of the chain length is present in all
fractions but in different proportions giving rise to polydispersity. This is possible
because some of the longer chains are conformationally more flexible facilitating their
passage through the sieves of the filter. The apparent molecular weight of the sulfated
fractions of DHPs was measured using SEC with PSS as standards.

We have employed the use of chain lengths and difference in the number obtained
between the sulfated and unsulfated fractions to get an insight into the apparent number
sulfates present. The calculation for number of sulfate groups turns out to be 1-1.8 per
monomer of CD and 0.5-0.8 sulfates per monomer of FD. Further, we attempted to obtain
a correlation between sulfates group obtained by chromatography and elemental analysis.
The number of sulfates for CDS30, CDS10, FDS30 and FDS10 using elemental analysis
were found to be 0.38, 0.33, 0.2 and 0.16 per monomer. The level of sulfation determined
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using both the techniques differ by 3-4-fold but the ratio between the sulfates remain the
same. This can be attributed to two things; first, the highly heterogeneous nature of the
samples and second the methods used to determine them. SEC measures the hydrodynamic volume of the sample, hence for similar size molecules the molecular weights,
might be different if the conformations are different. One sample might carry more
solvent molecules with it than the other increasing its overall size and hence the apparent
molecular weight.

Detailed structural characterization involving the exact type of inter-monomeric linkages
is very challenging. The

13

C-NMR just like the IR revert only functional group

information on these complex samples. Due to lack of powerful mass spectroscopy
techniques and expertise in polymer chemistry assigning linkages based on daughter ions
for this intricate mixture is not very reliable. All the functionality of the starting
monomer; hydroxyl, -carboxylic acid, aliphatic side chains, aromatic backbone and
methoxy (in case of FA) are retained in oligomers as evident by NMR.

Working with such a complex mixture would limit the discrete assignment of structures
despite the availability of modern and powerful techniques like NMR, MS and XRD (Xray diffraction). This drawback is outweighed by the fact that the mixture presents an
opportunity for high throughput screening of a large library, which would yield an
effective structure(s) rather than a discrete one. In the case of carboxylated lignins it is
combinatorial because of the nearly random coupling of radicals.
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The anticoagulation properties of DHP fractions were tested using an in vitro assay to
assess APTT and PT. The results reveal that all the fractions are able to prolong the
plasma clotting time for both APTT and PT assays. In addition, all samples show greater
potency prolonging the clotting time in the PT assay compared to enoxaparin, a marketed
LMWH used in clinical settings. The sulfated and unsulfated CD and FD fractions were
2.5 to 225- fold weaker in the APTT assay compared to enoxaprain, whereas in PT assay
the change observed ranged from 0.1 to 10-fold based on the size of the oligomers
(figure 25a & b). The fraction implies that some of the samples were more potent in
prolonging the clotting time compared to enoxaparin. Overall, it is evident from this
study that the activity is a size dependent phenomenon, where larger samples are more
active than the smaller ones. In addition, the larger samples are better in executing the
coagulation through the intrinsic pathway. It is possible that the significant hydrophobic
character of DHPs induces binding to cells resulting in significant sequestering of active
agent. It is likely that this non-specific binding will be reduced with homogeneous,
synthetic small molecules. Interestingly, the difference between sulfated and unsulfated
samples in prolonging the clotting time was not huge. Sulfated CD fractions were better
than unsulfated CD fractions by 1.3-3.9-fold and in case of FD fractions the difference
was not more than 2.3-fold (figure 26). This suggest that sulfation in not very critical as
is the case with heparins, where it is the root cause of numerous side effects. Finally,
since the samples work through both the coagulation cascade it lead us to predict that
either the samples are inhibiting numerous coagulation factors in the cascade or it worked
through the common pathway by either inhibiting thrombin and/or fXa, just like the
parent sulfated DHPs reported by our lab.
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Figure 25. Comparison of sulfated and unsulfated DHP fractions against enoxaparin
When compared with DHP fractions, enoxaparin is more potent in APTT assay, while in case of
PT assay only the higher fractions are more potent than enoxaparin.
*For comparison purposes of DHP fractions in PT assay, the fold concentrations have been
further enhanced by 10-fold. Hence, the actual value of enoxaparin, which is 1, shows up as 10.
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Figure 26. Comparison between sulfated and unsulfated DHP fractions in the APTT and PT
assays.
A) Comparison for APPT results and B) PT results

In the light of our prediction we carried out direct enzyme inhibition studies on thrombin
and fXa, which also revealed the mechanistic difference between our DHP samples and
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enoxaparin. All our samples directly inhibited the hydrolysis of appropriate chromogenic
substrate by thrombin and fXa, whereas enoxaparin is not a direct inhibitor of these
proteases. The IC50 values for sulfated and unsulfated samples ranged from ten’s of
nanomolar to micromolar; the difference between the most and least active being ~3800fold. As observed in the clotting assays the sulfated samples were more active than the
unsulfated ones ranged from 1.2-3.7-fold based on the size of the sample (figure 27).
And the difference within the unsulfated and sulfated group of samples ranged from 20 to
80-fold with the larger samples being more active the smaller ones (figure 28). Overall,
this study suggests that the unsulfated DHPs possess size-dependent direct inhibition of
thrombin and fXa, which are mechanistically different from heparins that work through
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Figure 27. Comparison between sulfated and unsulfated DHP fractions for their potency in
inhibiting thrombin and fXa.
Fold concentration was calculated by taking ratio of IC50 of unsulfated:sulfated fractions,
indicative of greater potency of sulfated fractions.
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Figure 28. Size Dependent comparison of DHP fractions for their potency in inhibiting
thrombin (A) and fXa (B).

Note: Sulfated DHP mixtures have been screened for other factors in the coagulation
cascade and were found not to inhibit any enzyme up to 3 mM concentration. Also, these
have been tested in presence of AT and the activity is not affected by more than 2-fold
suggesting that our samples are indeed inhibitors of thrombin and fXa.

In-vitro toxicity studies show that our DHP samples are not toxic up to a concentration of
500 µg/mL. All fractions show excellent cell viability at the highest concentration used
with the worst one 30FD showing more than 80% cell viability.

2.6

Conclusion

Although the heterogeneous and polydisperse nature of these DHP oligomers are
structurally difficult to characterize it presents us with a wealth of information that could
be used for rational design of advanced molecules. The molecules present in the mixture
have a common scaffold of lignin carboxylate. Unsulfated DHPs have a reduced overall
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negativity, which would arise only from the carboxylates on each monomer. This
reduction in the overall anionic character of DHPs could potentially overcome the
numerous unwanted interactions the sulfated DHPs might make while interacting with
the serine proteases, thrombin and fXa. In order to find a sequence like the heparin
pentasaccharide our chain length dependence studies revealed that an octamer size might
be just right to work with, which can be finely tuned to generate more potent molecules.
The other plausible strategy might be to further reduce the size to that of a tetramer or a
hexamer and have strategically located functional groups that interact with the residues in
the proteinase binding site and bring about inhibition. The samples represented in here, in
an attempt to mimic heparin have a complete different mechanism of action. Heparins are
indirect inhibitors, whereas our samples are direct inhibitors of thrombin and fXa.

On the whole, this entire exercise entails that it may be possible to design un-sulfated,
synthetic molecules with an optimum size that would possess unique mechanism of
action. A specific advantage expected of these un-sulfated homogeneous DHP-based
structures is that absence of sulfate group would make the molecules orally bioavailable.
This does not imply that our novel molecules will be clinically effective. Though in-vitro
studies suggest that our samples are not toxic up to a concentration of 0.5 g/L, in-vivo
toxicity studies will have to be performed to ascertain that these novel structures do not
induce abnormal effects. An important point to note in this regard is that in-vivo
enoxaparin does not prolong PT and APPT at concentrations sufficient to anticoagulate
suggesting that in-vitro potency does not translate directly into in-vivo effectiveness. Yet,
the results described here suggest that the novel structures of DHPs with optimum size
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and strategically placed functional groups may lead to a new class of potent
anticoagulants.
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CHAPTER 03
Novel and Specific Direct Thrombin Inhibitor

3.1

Background

Our earlier studies on DHPs had shown that it might be possible to design a potent
anticoagulant that would possess an optimal size with some anionic character and
hydrophobicity. In the same study we had postulated that our DHPs contain mainly two
types of linkages β-O-4 and β-5. The chain length and the linkage types were the main
reason for the tremendous heterogeneity and polydispersity introduced in the DHP
samples. Also, our DHP samples were found to be dual inhibitors of thrombin and fXa.
As described earlier, multienzyme targeting is the main drawback that leads to numerous
side effects that heparin carries. Our goal was to reduce the non-specific interaction as
much as possible. Heparin targets several enzymes in the coagulation cascade, which we
were able to overcome with our DHPs restricting it to act only as a dual inhibitor. After
studying the size dependency on enzyme inhibition the next logical step was to study the
structural decency. To study the inhibition arising from structural specificity we
synthesized DHPs with only β-O-4 type linkages, which will be referred as TK. The other
notable modification in TK was the absence of carboxylate groups. As we believed that
some anionic character was essential for the protease inhibition we derivatized the
hydroxyl groups on TK to the sulfates, and this derivative is labeled as TKS. This chapter
refers to the study of TKS as a specific inhibitor of thrombin and as a potential
anticoagulant.
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3.2

Experimental Methods

3.2.1 Proteins, biological fluids and chemicals
Human plasma proteinases, fVIIa, fIXa, fXa, fXIa and α-thrombin, were purchased from
Haematologic Technologies (Essex Junction, VT). Stock solutions of proteins were
prepared as follows: For fVIIa 25 mM HEPES buffer, pH 7.4, containing 100 mM NaCl
and 5 mM CaCl2. For fIXa 100 mM HEPES buffer, pH 8, containing 100 mM NaCl and
10 mM CaCl2. For fXa 20 mM Sodium phosphate buffer, pH 7.4, 0.1mM EDTA, 0.1%
PEG 8000. For fXIa and thrombin 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM
NaCl and 2.5 mM CaCl2, 0.1% PEG 8000. Chromogenic substrates used - Spectrozyme
FVIIa

(methanesulphonyl-D-cyclohexylalanyl-butyl-Argp-nitroanilide),

FIXa

(D-Leu-Phe-Gly-Arg-pnitroanilide),

Spectrozyme

FXa

Spectrozyme

(Methoxycarbonyl-

Dcyclohexylglycyl-Gyl-Arg-p-nitroanilide), Spectrozyme TH (H-DhexahydrotyrosolAla-Arg-p-nitroanilide). All substrates were purchased from American Diagnostica
(Greenwich, CT). Competitive ligands used - Exosite 1 ligand Tyr63-sulfated hirudin(54-65) labeled with 5-(carboxy)fluorescein ([5F]-Hir[54-65](SO3-)). Exosite 2 ligand
unfractionated porcine heparin (Sigma-Aldrich St. Louis, MO). Plasma and blood work –
Pooled citrated human plasma for coagulation time assays (Valley Biomedical
Winchester, VA). Activated partial thromboplastin time reagent containing ellagic acid
(APTT-LS), thromboplastin-D and 25 mM CaCl2 (Fisher Diagnostics Middletown, VA)
Fresh human whole blood (self donor not on any medication for 4 weeks before sample
collection) was collected in tubes containing sodium citrate 3.2% (0.109M). LMWH (MR
5,060 Da), TEAST complex (Sigma St. Louis, MO). Enoxaparin (MR 4,500 Da) (Aventis
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Pharmaceuticals). All other chemicals were analytical reagent grade from either Sigma
Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used as obtained.

3.2.2 Synthesis of TKS
TK, a β-O-4 polymer was obtained from Takao Kishimoto and sulfated as described
below. Figure 29 shows the

13

C-NMR spectra of TK. Sulfation of TK was carried out

using TEAST as described earlier. Briefly, TK was sulfated with TEAST complex.
Briefly, dry TK powder (50 mg) was dissolved in dry DMF (15 mL) containing TEAST
(200 mg) and stirred for 24 h at 60 °C. After the removal of most of the DMF in vacuo,
the remaining product was taken up in 30% aqueous sodium acetate, the sodium salt
precipitated using ~10 volume of cold ethanol. The precipitated product was further
purified using dialysis membrane (MWCO 5K).

Figure 29. 13C-NMR spectra of β-O-4 type artificial lignin polymer.126
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3.2.3 Molecular

weight

determination

of

TKS

using

size

exclusion

chromatography (SEC).
The apparent number and weight average molecular weight of TKS was determined using
SEC on a Shimadzu chromatography system composed of LC10Ai pumps and a SPD10A VP UV-Vis detector controlled by a SCL-10A VP system controller connected to a
computer. TKS was eluted on an Asahipak GS320 HQ column with an isocratic flow rate
of 0.7 mL/min of 0.1 N NaOH at pH 11.0. The wavelength of detection for fractions was
set to 280 nm. Polystyrene sulfonate standards (PSS) were used for calibration purposes.
The relationship between logarithm of the molecular weight and the elution volume (V)
of the standards was found to be linear with a correlation co-efficient of 0.99. Each
chromatogram was sliced into 1000 time periods providing 1000 MR with the
corresponding absorbance (A) values. These values were used to calculate MN, MW and P
parameters from equations 1, 2 and 3, respectively, for TKS.

MN =

∑ Ai × Mi
∑ Ai

∑ Ai × Mi2
MW =
∑ Ai × Mi

…… (1)

P=

MW
MN

…… (2)

…… (3)

3.2.4 Direct TKS inhibition of coagulation proteinases.
Direct inhibition of fVII, fIX, fXa, fXIa and thrombin by TKS was determined using
chromogenic substrate hydrolysis assays at physiological temperature. For these assays,
TKS having final concentrations ranging from 0.23 ng/mL to 230 μg/mL was used with
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appropriate buffer system in PEG 20,000-coated polystyrene cuvettes. The proteinase
solution was then added each time to yield final concentrations ranging from 1 to 10 nM
of each enzyme. The experiment was carried out at physiological temperature with an
incubation time of 10 minutes. Following incubation, appropriate amount of chromogenic
substrate was rapidly added to yield a final concentration of 20 to 50µM. The residual
thrombin activity was quantified by measuring the initial rate of hydrolysis from the
linear increase in absorbance at 405 nm as a function of time under conditions wherein
less than 10% substrate is consumed. Relative residual proteinase activity at each activity
measured under otherwise identical conditions, except for the absence of TKS. Logistic
equation 4 was used to fit the dose dependence of residual proteinase activity to obtain
IC50.

Y = YO +

YM − YO

…... (4)

1 + 10(log[L]O − log IC50) × HC

In this equation Y is the ratio of residual thrombin activity in the presence of TKS to that
in its absence; YM and Y0 are the maximum and minimum possible values of the
fractional residual thrombin activity, respectively; IC50 is the concentration of TKS that
results in 50% inhibition of enzyme activity, and HS is the Hill slope. HS does not
represent co-operativity because TKS is a polydisperse species that may possess multiple
binding modes and geometries. Sigmaplot 10.0 (SPSS, Inc. Chicago, IL) was used to
perform non-linear curve fitting in which YM, YO, IC50 and HS were allowed to float.
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3.2.5 Michaelis-Menten kinetics of substrate hydrolysis by thrombin in the
presence of TKS.
Several concentrations of Spectrozyme TH (0.5 to 40 μM) were treated with by 4 nM
thrombin in presence of fixed concentration of TKS (0 - 2.3 μg/mL). The initial rate of
substrate hydrolysis was monitored from the linear increase in A405 in 20 mM Tris-HCl
buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 at 25 °C.
The data obtained was fitted by the standard Michaelis-Menten equation to calculate that
apparent KM and VMAX.

3.2.6 Competitive binding studies with exosite ligands
TKS-dependent thrombin inhibition studies in the presence of [5F]-Hir[54-65](SO3-) or
porcine heparin were performed in a manner similar to that described above using the
chromogenic substrate hydrolysis assay. Briefly, a solution of TKS (0 - 23 µg/mL) and
thrombin (4nM) was incubated for 10 minutes at 37°C with either [5F]-Hir[54-65](SO3-) (0
– 86 nM) or porcine heparin (0 – 100 M) in 20 mM Tris-HCl buffer, pH 7.4, containing 100
mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000. Following incubation, Spectrozyme TH was

added to yield a final concentration of 20µM and its hydrolysis was measured as the
initial change in absorbance at 405 measured. The molecular weight of bovine heparin
was assumed to be 15000 Da, as reported in the literature. The dose-dependence of the
fractional residual proteinase activity at each concentration of the competitor was fitted
by equation 4 to obtain the apparent concentration of TKS required to reduce thrombin
activity to 50% of its initial value (IC50,app).
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3.2.7 Prothrombin time and Activated Partial Thromboplastin Time for plasma
clotting assays in presence of TKS
Clotting time was determined in a standard 1-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD). For PT and APTT assays, the
reagents were pre-warmed to 37 °C. For PT assays, 10 μL the anticoagulant (or the
reference molecule) was mixed with 90 μL of citrated human plasma, incubated for 30 s
at 37 °C quickly followed by addition of 200 μL pre-warmed thromboplastin. For APTT
assays, 10 μL of the anticoagulant was mixed with 90 μL citrated human plasma and 100
μL 0.2% ellagic acid. After incubation for 240 s, clotting was initiated by quickly adding
100 μL of 25 mM CaCl2. Each experiment was performed in duplicate. The averaged
data was fitted by a quadratic equation to calculate the concentration of the anticoagulant
necessary to double the clotting time (2 × PT or 2 × APTT).

3.2.8 Thromboelastograph (TEG®) Analysis of Clot Formation in the Presence of
TKS
The assays were performed using Thromboelastograph® Coagulation Analyzer 5000
(TEG®) (Haemoscope Corporation Niles, IL). Typically, these assays are performed to
analyze the rate and structure of a clotting sample and its breakdown. Briefly, in the
assays 20 μL of 200 mM CaCl2 was transferred into the HaemoscopeTM disposable cup,
oscillating through 4°45’ angle at 0.1 Hz. This was followed by the addition of a mixture
of 340 μL of sodium citrated whole blood containing 10 μL the anticoagulant or saline
(control) at 37 °C. This recalcification initiates clot formation in the TEG® coagulation
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analyzer, which operates until all necessary data collection (R, K, α and MA) is
completed in an automated manner.

3.2.9 Hemostasis Analysis System (HASTM) Analysis of Clot Formation in the
presence of TKS
Analysis of platelet function, clot formation and structure was performed using the
HASTM (Hemodyne, Inc., Richmond, VA). A mixture of 700 μl of citrated whole blood
and 10 μl of the anticoagulant or saline (control) was co-incubated at room temperature
for 5 minutes and then 700 μl was placed in a disposable cup. Clotting was initiated with
addition of 50 μl of 150 mM CaCl2 to the blood – anticoagulant mixture to give a final
CaCl2 concentration of 10 mM, while the cone was simultaneously lowered into the
recalcified blood sample. As the clotting proceeds, platelets attach to both surfaces
generating tension within the fibrin meshwork. This tension is measured with a
displacement transducer in terms of platelet contractile force (PCF). The onset of PCF is
a measure of thrombin generation time (TGT), while clot elastic modulus (CEM) is the
ratio of the applied force (stress) by the transducer to the measured displacement (strain).
The HASTM system operates in an automated manner until all data is collected.
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3.3

RESULTS

3.3.1 Structure of TKS
TK was prepared by Kishimoto et al. in a multi-step synthesis (figure 30). Synthesis of
TK results in generation of mixture of oligomeric species of β–O-4 type linked lignin that
ranged up to 20 monomer units in size. TK is thus structurally homogeneous but highly
polydispered mixture of molecules a property shared with heparins. However, the
aromatic scaffold makes TK more hydrophobic in nature as opposed to heparins. TK
completely lacks the anionic character that might be critical to make fruitful interactions
with the electropositive site on thrombin. This void was filled with introduction sulfate
moieties imparting an overall anionic feature to TK.
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Figure 30. Schematic representation for synthesis of TKS126
TK was synthesized in a multistep process, which was ultimately sulfated using TEAST-complex
to yield TKS.
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3.3.2 Size Determination of TKS
Apparent molecular weight of TKS was determined with SEC using 0.1N NaOH at pH
11.0 as an eluent. MW, MN, MP and P for TKS were calculated using PSS as a reference
standard and were found to be 12,305 Da, 9,208 Da, 9,090 Da and 1.34 respectively. The
chromatograms were broad and had a good symmetry, indicating the polydisperse nature
of TKS (figure 31). Sulfated TK (TKS) retained the polydispersity as its parent TK.
6
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Figure 31. a) Standard curve generated using PSS for SEC b) SEC profiles of PSS and
TKS.
Chromatogram of TKS is fairly symmetrical eluting between PSS 6530 and PSS 13200
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3.3.3 Direct Inhibition Assay on Coagulation Proteinases.
TKS showed high potency in direct inhibition of thrombin as compared to some other
enzymes in the coagulation cascade. TKS direct inhibition of thrombin in absence of AT
was at least 91-5,000-fold better as compared to fVIIa, fIXa, fXa and fXIa under similar
pseudo first order experimental conditions (figure 32). In these experiments substrate
hydrolysis of spectrozyme TH was monitored using spectrophotometer. The residual
proteinase activity decreased with increase in the concentration of TKS. Whereas, the
known AT activator enoxaparin had no direct inhibitory effect on thrombin and fXa in
absence of AT. The decrease in the proteinase activity was fitted to a logistic dose
response equation 4 to obtain the IC50 value. TKS directly inhibits thrombin, fVIIa, fXa
and fXIa with IC50 values of 18.7 nM, 1.70 µM, 56 µM and 90 µM respectively (Table
09). TKS did not inhibit fIXa at all up to a concentration of 25 µM.
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Figure 32. Inhibition of blood coagulation proteases, thrombin, fXa, fXIa, fVIIa and fIXa
by TKS.
TKS inhibits thrombin at an IC50 value of 18.7 nM which is at least 91-fold more potent in
inhibiting thrombin compared to other coagulation proteases.

Table 09: Inhibition of coagulation enzymes by TKS

Proteinase

log IC50 (g/ml)

YO

Thrombin

-6.77

0.02

29

fVIIa

-4.80

0.10

31.3

fIXa

YM
1
3

100

NI

HS

IC50 (µM)

99

1

1.9

0.1

0.019

107

5

1.2

0.4

1.70

100

NA

.001
0.10

NA

fXa

-3.30

0.60

0

0

100

4

0.5

0.2

55.7

2.0

fXIa

-4.05

0.10

40

2

98

3

1.0

0.2

9.9

0.40

Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl,
2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes. Spectrozyme TH
was used as substrate and the residual enzyme activity in the presence of inhibitor was assessed by
measuring the initial rate of substrate hydrolysis at 405 nm. Logistic equation 4 was used to fit the
dose dependence of the residual enzyme activity to obtain log IC50, Y0, YM and HS values. See
Methods for details.
Errors represent ±1 SE

80

3.3.4 TKS Disturbs the Catalytic Machinery of Thrombin
To understand the molecular basis for TKS inhibition of thrombin, we studied the
Michaelis-Menten constants derived by non-linear regression analysis of the initial rate
versus Spectrozyme TH concentration profiles at pH 7.4 and 37 °C in the presence of
TKS (figure 33). Plots of the initial rates versus Spectrozyme TH concentration were
hyperbolic, as expected, from which the apparent Michaelis constant (KM,app) and
maximal velocity of the reaction (VMAX) were derived. The results show that although the
concentration of TKS increased from 0 µg/mL to 2.3 µg/mL (0 – 253nM), the KM,app
value fluctuated around 1.5 μM, or alternatively remained essentially invariant in the
range of 2.8 to 1.3 μM (Table 10). This suggests that the presence of TKS does not much
affect the binding of the chromogenic substrate to the active site of the enzyme. In
contrast, the VMAX value decreased steadily from a high of 25.5 mAbsU/min in the
absence of TKS to a low of 7.4 mAbsU/min at 2.3 µg/mL TKS corresponding to a
decrease in kCAT value from 42.8 to 12.4 s-1, respectively. Thus, the presence of TKS does
not directly affect the binding of substrate in the active site but indirectly brings about
structural changes in the active site of thrombin, which do not alter the formation of the
thrombin–Spectrozyme TH Michaelis complex, but significantly reduce the rate of
conversion of the complex into products.
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Figure 33: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in the
presence of TKS.
The initial rate of hydrolysis at various substrate concentrations was measured in pH 7.4 buffer
as described in ‘Experimental Procedures’. Solid lines represent non-linear regressional fits to
the data using the Michaelis-Menten equation.

Table 10: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in the
presence of TKS

[TKS]o (ng/ml)

KM (µM)

VMAX (mAU/min)

kcat (s-1)

0

2.8

0.2

25.5

0.7

42.8

0.3

11.5

1.7

0.3

20.0

1.0

33.6

0.3

115

1.3

0.1

14.8

0.1

24.9

1.2

230

1.6

0.3

11.5

0.5

19.3

0.2

2300

1.4

0.1

7.4

0.1

12.4

0.1

KM and VMAX were measured as described in ‘Experimental Procedures’.
Error represents 1 S.E.
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3.3.5 TKS Binds at the Heparin Binding Site of Thrombin
To test whether TKS binds in one of the two anion-binding sites, we sought to measure
the effect of a hirudin-based peptide, [5F]-Hir[54-65](SO3-), an exosite-1 binding ligand
on the IC50 values of TKS-inhibition of thrombin. Earlier studies have shown that [5F]Hir[54-65](SO3-) binds thrombin with 28 nM affinity in exosite-1 with 1:1 stoichiometry
and enhances the forward rate constant (kCAT) of Spectrozyme TH hydrolysis. Utilizing
this knowledge we studied the competition between these two ligands by measuring the
IC50,app values of thrombin inhibition by TKS in the presence of the dodecapeptide over a
concentration range up to 3.2-fold higher than the KD of the thrombin-[5F]-Hir[5465](SO3-) complex. The IC50,app values were measured in the standard dose-response
assay, which we had used to determine thrombin inhibition. As the concentration of the
dodecapeptide was increased from 0 to 86nM, IC50,app essentially remained unchanged
varying between 16 nM to 20 nM (figure 34a). This suggest that the interaction of [5F]Hir[54-65](SO3-) with thrombin does not affect TKS inhibition of thrombin. Thus, it
appears that TKS does not preferentially bind thrombin in anion-binding exosite I. A
similar enzyme inhibition study was carried out in presence of an exosite-2 binding
ligand (figure 34b). Exosite-2 ligand like bovine heparin does not affect the proteolytic
activity of thrombin, while TKS is a potent inhibitor. Thus, if TKS binds in or near the
heparin binding site, its inhibition potency is expected to decrease as a function of the
concentration of the competitor (Table 11). As the concentration of heparin was
increased from 0 μM to 100 μM, the IC50,app values of thrombin inhibition increases from
18 nM to 138 nM. This clearly implies that heparin is competing with TKS to bind in or
near the anionic-binding exosite-2 of thrombin.
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Figure 34. Inhibition of thrombin by TKS in presence of exosite-1 & 2 ligands
Competitive effect of [5F]-Hir[54-65](SO3-) (figure 29a) and porcine heparin (figure 29b) on
the inhibition of thrombin by TKS. Residual thrombin activity was measured through
Spectrozyme TH hydrolysis in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5
mM CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 37 OC in the presence of 0 and 86
nM [5F]-Hir[54-65](SO3-) and 0 -100 μM of porcine heparin. Solid lines represent fits using
the logistic equation 4 to obtain the apparent IC50, as described in ‘Experimental Procedures’.
Table 11: Inhibition of thrombin by TKS in the presence of hirugen analog [5F]-Hir[5465](SO3-) and porcine heparin
[Competitor]
0nM

log IC50
(mg/ml)

Y0

YM

HS

IC50 (ng/ml)

IC50 (nM)

-3.77

0.02

28.6

0.70

99.1

0.8

1.9

0.1

170

6.5

18.0

0.7

8.6nM

-3.72

0.04

22.8

0.12

106

2.2

1.1

0.1

187

17.0

20.6

1.9

86nM

-3.81

0.07

16.3

2.0

105

4.0

1.1

0.2

153

24.0

16.8

2.6

Hirugen

Porcine Heparin
0.2 μM

-3.65

0.03

25.9

1.1

98.7

1.2

1.6

0.1

222

14.0

24.4

1.5

2.0 μM

-3.47

0.02

26.3

0.9

97.8

0.9

1.8

0.1

340

16.0

37.4

1.8

20 μM

-3.18

0.03

24.3

1.4

95.9

1.1

1.6

0.2

655

49.0

72.1

5.4

100 μM

-2.90

0.05

28.2

1.8

99.7

1.0

0.9

0.1

1250

142.0 137.5

15.6

Logistic equation 4 was used to fit the dose dependence of the residual enzyme activity to obtain
log IC50, Y0, YM and HS values. See Methods for details.
Error represents 1 ±S.E.
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3.3.6 Effect on Clotting Times
PT and APTT are commonly used to assess the coagulation status of human plasma. TKS
exhibited a significant concentration-dependent prolongation of PT and APTT. A typical
parameter for describing anticoagulant activity in these assays is the concentration of the
anticoagulant needed for doubling the normal plasma clotting time (2 × PT or 2 × APTT).
The 2 × PT and 2 × APTT value for TKS was found to be 68.6 µg/mL (7.6µM) and 23.6
µg/mL (2.6µM), whereas that for enoxaparin was 75.3 μM and 1.2 μM respectively,
suggesting that TKS is 9.9-fold more potent in the PT assay and approximately 2.2-fold
weaker anticoagulant in the APTT assay as compared with enoxaparin (figure 35a & b).
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Figure 35: Plasma clotting assay performed using APTT and PT for TKS
a) & b) figures represent APTT and PT results TKS.
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3.3.7 Effect of TKS on whole blood clotting
Whole blood clotting is a dynamic process that involves many components, including
cells, which may alter anticoagulant potency. To compare TKS and enoxaparin in a
whole blood system, we employed TEG, a technique used in clinical settings for
following anticoagulation with LMWHs. TEG measures various responses of a formed
clot to shearing force. In this technique, a pin is inserted into an oscillating cup
containing whole blood. As fibrin polymerizes, the pin starts to move with the oscillating
cup, and the movement of the pin is recorded as amplitude, which in time reaches
maximum amplitude. The stronger the clot, the more the pin moves with the cup and the
higher the maximum amplitude. Shear elastic modulus strength (G), a measure of clot
stiffness, is calculated from maximum amplitude. Additionally, R and angle α are also
obtained in a TEG experiment. R is the time required for the initial fibrin formation,
whereas α is the acute angle in degrees between an extension of the R tracing and the
tangent of the maximum slope produced by the TEG tracing during clot stiffening. Angle
α is a measure of the rate of formation of three-dimensional fibrin network. Parameters
that affect maximum amplitude include fibrin concentration and structure, concentration
and functional state of platelets, deficiency of coagulation factors and the presence of
clotting inhibitors. TKS affects all the parameters R, α, maximum amplitude and G
parameters in a dose-dependent manner. Briefly, as the concentration of TKS increases
from 0 to 414 μg/mL, R increases from 7.7 to 25.9 min. Likewise, TKS lowers the value
of angle α from 56° for normal blood to 22° at the highest concentrations studied. This
indicates that the kinetics of fibrin polymerization and networking is significantly
retarded by the presence of TKS (figure 36). Enoxaparin exhibits similar characteristics,
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except that it is 7.9-fold more potent than TKS when comparisons are made at doubling
the R value from its value in the absence of any anticoagulants. Likewise, enoxaparin is
12.2-fold and 12.9-fold more potent when comparisons are made for a 50% reduction in

[TKS]O = 0 μM

0.02 μM

1.7 μM
8.6 μM
17.1 μM

Amplitude (mm)

Amplitude (mm)

the angle α and shear elastic modulus G, respectively (Table 12).



R

MA

Time

(min)

Time (min)
Figure 36. Effect of TKS on clot formation in whole blood using TEG.
Inset in shows a typical thromboelastogram expected of any anticoagulant. MA, R, α and G are
parameters obtained from TEG® analysis. See Methods for details. Figure shows change in
thromboelastograph as a function of increasing concentration of TKS.
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Table 12: Parameters obtained from thromboelastograph (TEG) study of TKS and
enoxaparin in human whole blood.a

TEG Parametersa

TKS

Enoxaparin

conc

Rb

αc

MAd

Ge

(μM)

(min)

(degrees)

(mm)

(Dynes/cm2)

0

7.7

56.0

61.0

7821

0.0171

8.9

50.5

50.5

7658

1.71

13.2

42.5

57.0

6628

8.6

16.9

43.0

55.5

6236

17.1

25.9

22.0

41.5

3547

0

7.0

59.0

56.5

6456.5

0.3

8.0

49.0

51

5204.0

0.44

9.5

39.5

51

5204.0

0.6

11.5

43.0

47.0

4434.0

0.75

14.0

41.0

46

4259.5

0.89

17.0

36.5

47.0

4434.0

1.0

17.0

31.5

42.0

3620.5

TEG parameters were obtained in an automated manner from the TEG coagulation analyzer.
See Experimental Procedures for a description of the setup. bReaction time R is the time interval
between the initiation of coagulation and the appearance of first detectable signal of no less than
2 mm in amplitude. cAngle α is the acute angle in degrees between an extension of the R value
tracing and the tangent of the maximum slope produced by the TEG tracing. dMaximum
amplitude (MA) is the maximum distance the pin of TEG moves at the end. eThe shear elastic
modulus strength (G) is a calculated parameter (G = 5000MA / (100 – MA) and is a measure of
clot strength.
a
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To further compare the whole blood anticoagulant potential of TKS with enoxaparin, we
performed an ex-vivo study using HAS, which measures the forces generated by platelets
within a clot. In this technique, the clot is allowed to form between a temperature
controlled lower surface (cup) and a parallel upper surface (cone). As the clot grows, it
attaches to both the surfaces, pulling the fibrin strands inward. This pull is measured by a
displacement transducer, which produces an electrical signal on the cone proportional to
the amount of force generated by the platelets. HAS also provides detailed information on
clot structure through the measurement of CEM, which is the ratio of stress induced by
platelets to strain arising from the change in clot thickness. PCF is observed to increase as
soon as thrombin is formed, suggesting that the appearance of PCF can be used as
surrogate marker for TGT, the minimal time required for production of thrombin
following initiation of clotting. In addition to its dependence on thrombin, PCF is
sensitive to platelet number, platelet metabolic status, presence of thrombin inhibitors and
the degree of glycoprotein IIb/IIIa exposure. Likewise, CEM is a complex parameter that
is sensitive to changes in clot structure, fibrinogen concentration, the rate of thrombin
generation and red blood cell flexibility, whereas TGT is sensitive to clotting factor
deficiencies, antithrombin concentration and the presence of anticoagulants. Low PCF
and CEM coupled with a prolonged TGT are associated with increased bleeding risk,
whereas elevated PCF and CEM paired with a decreased TGT are associated with
thrombotic disease states. TKS affects TGT, PCF and CEM parameters in a dosedependent manner with 6.7 μM TKS required to double the TGT value using HAS. This
effect parallels the results obtained in TEG. More importantly, the presence of TKS in
blood decreases PCF from 8 to 0.66 kdynes at 8.3 μM (figure 37a), whereas enoxaparin
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induces a PCF of 0.66 kdynes at 0.47 μM, a difference of 17.7-fold. Likewise, TKS
decreases CEM from 18.25 kdynes/cm2 for normal blood to 0.62 kdynes/cm2 at 8.3 μM
(figure 37b). Comparison of TKS for a 50% reduction in CEM values indicates that
enoxaparin is 23.5-fold more potent than TKS (Table 13). These results confirm that
TKS behaves in a manner similar to enoxaparin, except for the concentration at which it
is effective. When compared with FDS, TKS has slightly better potency in whole blood,
1.4 – 2.9-fold based on the parameter evaluated. This slight reduction in potency can be
attributed to the more heterogeneous nature of FDS, which is structurally more diverse
than TKS.
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Figure 37. Effect of TKS on platelet function in whole blood using HAS™.
HAS™ profiles obtained with show the variation in a) PCF and b) CEM, as a function of
concentration of TKS.
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Table 13: Parameters obtained from the Hemostasis Analysis System (HAS™) study of
TKS and enoxaparin in human whole blood.a

HAS™ Parametersa

TKS

Enoxaparin

Conc

TGTb

PCF c

CEMd

(µM)

(min)

0.0

6.25

8.00

18.25

0.008

5.05

7.27

12.00

0.83

6.55

5.82

6.31

4.17

11.25

3.30

3.94

8.3

13.55

0.66

0.62

0.0

3.55

7.60

21.60

0.146

5.15

5.30

15.10

0.218

9.05

3.60

12.70

0.346

11.00

2.80

8.50

0.437

12.45

0.90

2.90

(Kdynes) (Kdynes/cm2)

HAS™ parameters were obtained in an automated manner from the Hemostasis Analysis
System. See Experimental Procedures for a description of the setup. bThrombin generation
time is the time interval between the initiation of coagulation and the onset of detectable
platelet contractile force. cPlatelet contractile force describes the forces generated by platelets
during clot retraction. dClot elastic modulus is the ratio of the applied force (stress) to the
measured displacement of the clot.
a
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3.4

Discussion

In an effort to mimic heparin’s structural features we have reported at least 3 different
types of carboxylated lignins. All three were a fairly complex mixture of molecules
arising from different sizes and linkage types. Further, we studied the size based potency
of one of the better DHPs, FD while still retaining the structural heterogeneity. In our
continuing efforts to achieve relevant and meaningful information out of this complex
mixture we have synthesized structurally homogenous lignin-like mixture. The main
difference from the earlier DHPs is the lack of carboxylic acid functionality, which has
been replaced by sulfates to achieve an overall anionic nature.

While conducting the literature search for synthesis of a β-O-4 type lignin polymers we
stumbled across Kishimoto and co-workers who have already synthesized this
structurally homogenous mixture.126 Before going through an arduous task of multi-step
synthesis we obtained 100 mg sample from Dr. Kishimoto’s group as a generous gift.
Note: A fellow graduate student, Akul Mehta is currently working on synthesis of TK to
generate larger amounts to be studied in animal models.

TK polymer received as a gift was subjected to sulfation using TEAST complex to yield
TKS. The molecular weight characteristics of TKS were evaluated using SEC. The MN
and MP were found to be 9,208 and 9,090 respectively suggesting that there is equal
distribution of samples on either side of the bell shaped curve indicative of a symmetric
chromatogram. The polydispersity derived from the relationship between MW (12,305)
and Mn (9,208) indicated that TKS like DHPs are polydisperse in nature with a P value
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of 1.34. When compared with DHPs (P = 2.0 - 4.0) TKS is fairly less polydisperse
implying the advantage of controlled polymerization over random polymerization. When
DHPs are formed the enzyme horse radish peroxidase (HRP) randomly couples the
monomers to generate β-O-4 and β-5 linked structures as opposed to synthetically made
TKS, where the linkages are formed as directed to yield just the β-O-4 type polymer.
Using the per sulfated form of the starting monomer the apparent chain length was
calculated to be 25.

Since TKS was a result of the complex DHP mixture of FA, we opted first to evaluate
TKS for direct inhibition of the coagulation factors in the common pathway rather than
conduct the APPT and PT assays. TKS potently inhibited thrombin with an IC50 of 18.7
nM, which is a 2.7-fold improvement over the most potent sulfated FD. Interestingly,
TKS could inhibit fXa only at a very high concentration of 56µM. This is a 3000-fold
increase, which indicates the excellent specificity of TKS for thrombin over fXa. To
probe into the specificity of TKS, which lacks the carboxylic acid group we chose to
screen several other important factors in the coagulation cascade. The IC50 values
obtained for inhibition of fVIIa, and fXIa were 1.7 µM and 90 µM and TKS completely
failed to inhibit fIXa at concentrations as high as 25 µM. TKS inhibition for fVIIa and
fIXa being 94.4-fold and 5000-fold weaker than thrombin strengthens the conclusion that
indeed TKS is a specific inhibitor of thrombin. Probably, this also implies that thrombin
specificity arises due to the structural uniqueness of TKS, which possess only the β-O-4
type linkages and not due to the absence of carboxylic acids. Presence of sulfates instead
of carboxylic acid imparting such a huge specificity in inhibition seems highly unlikely,
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though it remains to be determined if it was true. Also, from our previous work on
sulfated and unsulfated DHP fractions it is evident that there is none to insignificant
change (1.07 to 1.4-fold) in the specificity with the introduction of sulfates.

To understand the mechanism of inhibition of TKS by which it brings about the change
in binding of the substrate at the active site we chose to study all three potential binding
sites on thrombin. We performed Michaelis-Menten type kinetics to investigate the active
site binding phenomenon and competitive ligand binding studies to probe the allostericity
for exosite-1 and 2. TKS did not compete with the substrate during binding but it brought
about the change in the hydrolysis of the substrate through allosteric modulation. This
was apparent by the decrease in the VMAX and KCAT values, whereas the Michaelis-Menten
constant remained unchanged. The competitive ligand binding studies with site specific
ligands [5F]-Hir[54-65](SO3-) (exosite-1) and heparin (exosite-2) revealed that TKS
competes with heparin to bind at the exosite-2 of thrombin. This was concluded based on
worsening of the IC50,app values for TKS inhibition of thrombin with increasing
concentration of exosite-2 competitor. And in case of exosite-1 ligand a very insignificant
change in the IC50,app values was observed. At this point it is important to recall that both
the exosites are electropositive with exosite-2 being less compensated and less
hydrophobic than exosite-1.

We further evaluated TKS for their effect as an anticoagulant in human plasma and whole
blood. This is an important study that had to be undertaken considering the fact that
heparins and LMWH non-specifically bind to plasma proteins resulting in the numerous
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side effects they carry. The plasma anticoagulation effect of TKS was tested using APTT
and PT assays, which would assess its ability to work via the intrinsic and the extrinsic
pathway of the coagulation system. Comparative studies with enoxaprain, a LMWH
revealed that TKS was 2.2-fold weaker in the APTT assay, while it was 9.9-fold more
potent in acting through the extrinsic pathway. Based on these comparisons it is hard to
conclude if TKS evades non-specific interactions with the plasma proteins as both
enoxaparin and TKS work through a complete different mechanism. A similar study
using an FDA approved DTI would yield a more relevant comparison. Nevertheless, the
plasma study indicates that TKS still retains its anticoagulant potency when subjected to
a higher system like plasma. Also, when compared with the most potent sulfated FD
fraction, TKS has essentially same effect on APTT and PT implying a cumulative effect
in case of DHPs, which works through thrombin and fXa. Hence, we can conclude that
though TKS is more potent in inhibiting thrombin as compared to DHPs they bring about
the same effect in higher systems like plasma through a complete different mechanism.

Based on the results achieved from plasma studies TKS was subjected to a more complex
system to prove its anticoagulant potency. Whole human blood assays performed using
TEG® and HAS™ indicated that TKS was 7.9-12.9-fold and 17.7-23.5-fold less active in
comparison with enoxaparin. It is possible that the significant hydrophobic character of
TKS induces binding to cells resulting in significant sequestering of active agent. It is
likely that this non-specific binding will be reduced with less polydisperse, synthetic
small molecules.

95

Overall, TKS demonstrates a major improvement over DHPs in terms structural
homogeneity, which has led to a greater specificity in targeting thrombin. It also
possesses a better plasma and whole blood anticoagulation activity suggesting the
reduction in the non-specific binding of the plasma proteins. Toxicity studies have to be
performed to ascertain that TKS do not induce abnormal effects.

3.5

Conclusion

The entire study points towards specificity of TKS, which arises due to the β-O-4 type of
linkage. Our DHPs are structural heterogeneous leading us to believe that structural
features like the linkages are dictating the specificity in targeting enzymes. We cannot
hold back to hypothesize that β-5 type linkages, which is the second most abundant in
lignin and our enzymatically synthesized DHPs might be fXa specific. This hypothesis if
proven would revolutionize the entire process of anticoagulant drug design. Also, studies
from the previous chapter indicate that an octamer might be the optimum working range.
Utilizing the information from these studies a tetramer of β-O-4 type synthesized would
be an appropriate chain length to start with, which can be easily converted to an octamer
by combining the two tetramers. Further, slight functional group modification might be
essential to achieve greater potencies. By and large, this study puts forward a new class
of molecule as a potential anticoagulant.
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CHAPTRT 04
Non-sulfated Cinnamic Acid-Based Lignins As Potent Antagonists of HSV-1 Entry
Into Cells

4.1

Background

4.1.1 Introduction
Herpes viruses are a leading cause of human viral disease, second only to influenza and
cold viruses. They are capable of causing overt disease or remaining silent for many
years only to be reactivated. The herpes family contains more than hundred viruses that
infect organisms of which eight are known to infect human beings. In general herpes
viruses cannot survive at room temperature, especially outside of the body where they
can dry out. Direct contact between susceptible cells and secretions of infected cells is
usually required for transmission. The herpes virus has an excellent ability to remain
dormant for years and the sporadic reappearance of herpetic lesions is a perturbing aspect
of the infection.127-128 For reasons that are poorly understood the latent, inactive, infection
can become active and cause illness. Reactivation of dormant viruses occurs when they
start to reproduce inside cells, eventually causing them to burst and spread the virus
particles to propagate infection.129 The virus particles can also attack neurons causing
neurotropic disorders. Breakage of latency can occur in these cells and the virus can
travel back down the nerve axon, where lesions are seen.130 This means that recurrence of
infection (and therefore symptoms) can occur at the same site as the initial infection.
There are several agents that seem to trigger recurrence, most of which are stress-related.
It also appears that exposure to strong sunlight and perhaps fever can lead to recurrence.
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These factors may cause some degree of immune suppression that leads to renewal of
virus proliferation in the nerve cell.

Herpes infections are highly prevalent affecting at least 1 in 3 individuals in the US. Of
the eight strains known to infect humans, herpes simplex virus, HSV-1 and HSV-2 are
the most common ones. Refer Table 14 for the list of 8 strains of herpes virus and their
site of latency. The primary difference between the two is their “site of preference” when
establishing latency in the body.131 HSV-1 usually establishes latency in the trigeminal
ganglion, a collection of nerve cells found in close proximity to the ears and recurring
herpes outbreaks will commonly occur around the mouth or facial region. HSV-2 usually
establishes latency in the sacral ganglion, a collection of nerves found at the lower base
of the spine and recurring outbreaks will commonly occur in the genital region. Though
this is the most commonly noted difference, it is not absolute. Both HSV-1 and HSV-2
can reside in either or both parts of the body and infect orally and/or genitally.

HSV-1 is often transmitted in childhood through kissing, but can be transmitted at any
age through direct skin-to-skin contact. In the US about 50% of adults are carrier of
HSV-1 antibodies by the time they are young adults and by the time they are 50 years 8090% of Americans carry HSV-1 antibodies.132 For both types, at least two-thirds of
infected people have no symptoms, or symptoms too mild to notice such as cold sores.
However, both types can recur and spread even when no symptoms are present.
Occasionally, the virus spreads to the central nervous system causing meningitis or
encephalitis.

So

far,

vaccines,

ILs,

IFNs,
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therapeutic

proteins,

antibodies,

immunomodulators and small-molecule drugs with specific or non-specific modes of
action lacked either efficacy or the required safety profile to replace the nucleosidic drugs
acyclovir, valacyclovir, penciclovir and famciclovir as the first choice of treatment.133-135
All of these drugs are classified, as “Nucleoside Antimetabolites” and they are inhibitors
of viral DNA polymerase. These drugs are phosphorylated by viral thymidylate kinase to
the monophosphate, which is further bioactivated to the triphosphate. The triphosphate is
selective inhibitor of viral DNA polymerase.

4.1.2 Diseases caused by the Herpes virus
Oral herpes, Herpes keratitis, Herpes whitlow, Herpes gladiatorum, Eczema herpeticum,
Genital herpes, HSV proctitis, HSV Encephalitis, HSV Meningitis, HSV infection of
neonates (This results from HSV-2 and is often fatal, although such infections are rare.
Infection is especially possible if the mother is shedding virus at the time of delivery).

Table 14: Types of herpes viruses infecting humans and the site of latency
Acronym

Name

Site of Latency

HSV-1

Herpes Simplex Virus 1

Sensory Neurons

HSV-2

Herpes Simplex Virus 2

Sensory Neurons

VZV

Varicella-Zoster Virus

Sensory Neurons

CMV

Cytomegalo Virus

EBV

Epstein Barr Virus

Monocytes, Endothelial
cells
B Lymphocytes

HHV-6

Human Herpes Virus 6

T cells, Monocytes

HHV-7

Human Herpes Virus 7

T cells, Monocytes

HHV-8

Kaposi Sarcoma Associated Virus

Monocytes ?
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4.1.3 Structure of Herpes Virus

glycoproteins

lipid bilayered
envelope
capsid

double
stranded
DNA

tegument

Figure 38. General structure of the herpes virus

The general structure of the herpes virus consists of the following: (refer figure 38)

Envelope
Herpes viruses are enveloped viruses with close to a dozen glycoproteins attached to the
cell surface. They bud from the inner nuclear membrane, which has been modified by the
insertion of herpes glycoproteins. These glycoproteins determine the cell to be infected.
The viral membrane is quite fragile and a virus with a damaged envelope is not
infectious. Besides drying, the virus is also sensitive to acids, detergents and organic
solvents as might be expected for a virus with a lipid envelope.
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Tegument
The space between the envelope and the capsid is the amorphous tegument. This contains
virally-encoded proteins, such as VP16 and vhs (virus host shut off), and enzymes that
are involved in the initiation of replication.

Capsid
These viruses have a doughnut shaped capsomere of about 100-200 nm in diameter with
an icosahedral proteinaceous nucleocapsid. The latter contains 162 capsomeres or
morphological elements.

Genome
Inner core of the herpes viruses have a linear double stranded DNA viral genome
encoding about 100-200 genes. Many of these proteins (about half) are not directly
involved in the virus structure or controlling its replication, but function in the interaction
with the host cell or the immune response of the host. HSV-1 and HSV-2 have
characteristic resemblances in their genome. The genome of HSV encodes a number of
enzymes: DNA-dependent DNA polymerase, thymidine kinase (phosphorylates
thymidine and other nucleosides), ribonucleotide reductase (converts ribonucleotides to
deoxyribonucleotide) and serineprotease (converts a scaffolding protein to its final form).
The genome also encodes 11 surface glycoproteins. These are involved in attachment
(gB, gC, gD and gH), fusion of the viral membrane with that of the host cell (gB, gH and
gL), immune escape and other functions (gC, gE and gI), production of virus in cell
culture (gK), and unknown function (gG, gJ and gM).136-145
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4.1.4 HSV-1 Infection
HSV-1 infection of cells can be divided into two phases, the binding phase and the
penetration phase (figure 39). The first phase involves the binding of the viral
glycoprotein gC and/or gB to the glycosaminoglycans (GAGs) chains on cell surface
proteoglycans.146-148 The major type of GAG chain found on the cell surface is heparan
sulfate (HS). This initial binding is not sufficient for viral penetration, which further
involves fusion of the viral envelope with the cell membrane. This step involves
interaction of viral glycoprotein gD with one or several receptors for gD on the cell
surface, before the viral particle can fuse with the cell plasma membrane and the viral
capsid is released into the cytoplasm. The fusion process is a complex set of events
involving multiple interactions between various gD receptors on the cell surface and the
viral glycoprotein gD, gB and hetero-oligomers of gH and gL. Depending on the nature
of interaction and size of HS chain, a single chain may bind multiple viral ligands on a
virion.149-151 The entry receptors discovered to date fall into three categories. They
include HVEM (herpes virus entry mediator), a member of TNF receptor family, nectin-1
and nectin-2, members of the immunoglobin superfamily and specific site in HS
generated by certain 3-O-sulfotransferases (3-OST).152-160
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Figure 39. Pictorial representation of the mechanism of herpes virus entering into human
cell.

4.1.5 Evidence Showing Role of HS
There is convincing evidence indicating that HS is critical for HSV-1 adsorption on the
cell surface and its subsequent entry into cells.161-162 First, cells that are devoid of HS (but
not other GAGs) because of enzymatic treatment or genetic mutation are markedly less
susceptible to HSV-1. These cells have greatly reduced number of receptors for viral
binding. It has been shown that HSV-1 attaches weakly to HS-deficient Chinese hamster
ovary (CHO) cells.163-164 Second, soluble heparin, which is structurally similar to HS,
inhibits binding of viruses to cells, whereas the structurally less similar GAG chondroitin
sulfate fails to inhibit binding or infection. Third, gC and gB bind selectively and
independently to heparin-sepharose columns under physiological conditions. Also, degree
of sulfation of GAGs is an important determinant for recognition by viral glycoprotein
gB2.165 Heparin, which has higher degree of sulfation as compared to HS, is a better
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competitive inhibitor of gB2 binding.166 In 2002, Liu et.al have characterized a HS-based
octasaccharide that binds to HSV-I gD.167 The distinguishing feature in the composition
of the octasaccharide is the presence of 3-O-sulfate glucosamine residue, which is an
uncommon structural modification in heparin sulfate. Its presence in the HSV-I gD
binding sequence must probably confer specificity of interaction by generating a unique
protein binding site, hence assisting HSV-I entry into the cell.168 Thus, HS is required for
both viral binding and penetration –the two early events in infection. HS also plays
important role in attachment of other viruses such as the human immunodeficiency virus
(HIV) (E gp120 and gp41), dengue virus (gC, gE and gM), foot and mouth disease virus
(E VP1-4), vaccinia virus (E A27L), Sindbis virus (E2 glycoprotein), respiratory
syncytial virus, and Echovirus.169-174 In each of these viruses, cell surface HS is used for
gaining entry into the cell.

4.1.6 Heparan Sulfate
HS is the most complex polysaccharide on the surface of the mammalian cells. GAG
polysaccharides are long, polyanionic chains consisting of repeating disaccharide units.175
HS is a GAG covalently attached to the protein core (in the cell membrane - syndecan-1,
N-syndecan, fibroglycan, amphiglycan and glypican) of proteoglycans, which are
expressed on nearly all cell surfaces, in the extracellular matrices and are even segregated
into intracellular granules.176-177 Structurally, HS is a heterogeneous linear co-polymer of
glucosamine (GlcNp) and glucuronic acid (GlcAp) residues linked in a 1-4 manner, of
which the GlcNp residues are typically acetylated at 2- position (figure 40).178 Despite
this apparently simple monomeric disaccharide structure, HS perhaps represents the most
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structurally complex molecule nature biosynthesizes because of two critical, essentially
incomplete,

CH2OX

COO
O

O
OX

OH
O

O

OX

NHY

n

X = H or SO3Y = H or Ac or SO3-

Figure 40. General structure of heparan sulfate showing the disaccharide unit, glucosamine
and uronic acid residues linked in a 1-4 manner

structure modification steps. One, some GlcAp residues are epimerized to iduronic acid
(IdoAp) and two, incomplete sulfation occurs at the 3-O-, 6-O-, and 2-N positions of
GlcNp in addition to sulfation at 2-O-position of few IdoAp residues.178 This primary
structural diversity is further complicated by another level of complexity wherein sulfate
groups may cluster in small regions and form differentially charged domains. The
number of structural sequences possible with these variations, especially taking into
account the size recognized by proteins and receptors run into millions. The final
structure of HS depends upon the incompleteness of the reactions that occur during the
biosynthetic process. The modification process is more complete in heparin where the
final disaccharide IdoAp(2-OSO3)-GlcNpSO3(6-OSO3) represents up to 70% of the chain,
leading to a heavily O-sulfated polysaccharide with a high IdoAp/GlcAp ratio. In
contrast, the modifications that occur during the biosynthesis of HS are less extensive;
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leading to HS molecules characterized by lower IdoAp content and a lower overall
degree of O-sulfation and resulting in high heterogeneity of distribution of the sulfate
groups along the chain.179-182 This diversity arguably plays a key role in numerous
biological processes like maintaining cell surface architecture; modulating critical
biological events and also interacting with a variety of ligands. Typical concentrations of
HS proteoglycans on the cell surface are in the range of 105-106 molecules/cells as
measured in various cell culture systems. The interactions are largely electrostatic in
nature and depend on the distribution of hexuronic acid residues and sulfate groups along
the polysaccharide chain. The prolific expression of HS and their strong interactive
ability are two features that have made them attractive adhesion molecules providing
initial docking sites for all sorts of viruses and other microorganisms during their
evolution. In addition, the negative charge arising from sulfates/carboxylates on HS
makes it well suited to interact with positively charged basic amino acid domains on viral
proteins.

4.1.7 HS Mimics
HS plays a vital role in the entry of the HSV-1 into cells. Thus, structural or functional
mimics of HS are likely to competitively inhibit the entry of the virus into cells. In this
context, numerous sulfated molecules have been explored as mimics of HS in the
inhibition of HSV-1 entry into cells (figure 41).183 These include heparin and its
chemically modified derivatives, non-anticoagulant heparin, pentosan polysulfate,
dextran sulfate, sulfated maltoheptaose, fucan sulfate, fucoidans, spirulan, sulfated
galactans, and miscellaneous sulfated polysaccharides.184-186 These compounds compete
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with cell surface HS for binding to the virus particles and therefore are most active when
present during the attachment phase of the viral entry. Not unexpectedly, each HS mimic
found to-date as an inhibitor of viral entry has a linear polysaccharide backbone with
varying degrees of sulfation.
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Figure 41. Some of the sulfated polysaccharides that have been tried as heparan sulfate
mimics for HSV-1 inhibition activity.

A study of molecular weight dependence of infection inhibition activity shows that the
antiviral potency increases with increasing sulfation levels and length of chain. Yet,
detailed aspects of interactions at molecular level, their nature and contributions, the
order of interactions, and the step-wise molecular mechanism remains unclear.
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4.2

Rationale

From the literature study, it is clear that HS on the cell surface plays an imperative role in
assisting the entry of the HSV-1 into cells. Therefore, designing a drug that would inhibit
the entry of the virus at the very first stage and thus preventing any further proliferation
seems crucial. A simple rational drug approach that comes to mind is designing HS
mimics that would competitively inhibit the entry of the virus into cells. Literature survey
shows that HS mimics have been developed to competitively inhibit viral entry.
However, most HS mimics reported so far have been polysaccharide-based sulfated
molecules. In an effort to discover non-polysaccharide-based macromolecular mimics of
HS, we previously designed sulfated lignins, which are sulfated derivatives of the natural
biopolymer lignin.123-124,187-188 Lignin is a complex, heterogeneous polymer made up of
repeating phenylpropanoid units containing multiple hydroxyl groups (figure 42).189-190
Our sulfated lignins were found to be excellent antagonists of HSV and HIV infections of
cells.187-188 Although the biochemical chemical basis for the anti-HSV and anti-HIV
activity of sulfated lignins is not known, a plausible hypothesis relies on the similarity of
sulfated lignin’s electrostatic surface with that of HS.123 In contrast to sulfated
polysaccharide, the sulfated lignin scaffold that we proposed is an attractive alternative
because its phenylpropanoid units afford numerous opportunities for structural variations
to fine-tune biological activity. In addition, lignin can be rather easily synthesized in high
yields in the laboratory using enzymatic oxidative coupling. We reasoned that it should
be possible to devise a lignin scaffold that is completely devoid of sulfate moieties and
yet possess an electrostatic surface equivalent to that of HS so as to retain potent
antagonism of viral entry into cells. The average negative charge density of HS is nearly
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1.0-1.4.189-193 Thus, a lignin monomer containing one negative charge, which is not a
sulfate, for example, caffeic or ferulic acid is likely to afford a nonsulfated lignin polymer
with HS mimicking properties (figure 43).

We found that the two carboxylated lignins are not only potent inhibitors of HSV-1 entry
into mammalian cells, but are much more effective than sulfated lignins. In addition, the
CH2OH

CH2OH

H3CO

CH2OH

H3CO

OH

OH

para hydroxy cinnamyl
alcohol (coumaryl alcohol)

coniferyl alcohol

OCH3
OH

sinapyl alcohol

Figure 42. Monomers which serve as the precursor for lignin biosynthesis

results show that the shorter carboxylated lignins are very potent in preventing HSV-1
infection suggesting the possibility that structural features, in addition to carboxylate
groups, may be important. The results present major opportunities for developing orally
available small molecular weight lignin-based antiviral strategies.
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Figure 43. Structure of carboxylated lignins CD and FD obtained from horseradish
peroxidase-catalyzed oxidative coupling of caffeic and ferulic acid, respectively.
Carbon designations (α, β, 4, 5, and others), unique to the lignin field, are as shown. X can be
either -H or -OH. Oxidative coupling through radical intermediates give rises to oligomers with
different types of intermonomeric linkages. The most common linkages formed include β-O-4
and β-5. Other less common linkages include β-β, 5-5, and 5-O-4, for which oligomerization
tends to arrest chain growth.(ref) The length of the chain greatly depends on the conditions of
oligomerization.

4.3

Experimental Methods

4.3.1 Chemicals, Cells, and Viruses
Horseradish peroxidase (HRP) with activity of 250-330 units/mg was from Sigma (St.
Louis, MO). β-Galactosidase substrate o-nitrophenyl β-D-galactopyranoside (ONPG) was
performed from Pierce (Rockford, IL). High purity water, obtained from NERL
Diagnostics (RI, U.S.A.), was used in all experiments. Dr. Patricia Spear (Northwestern
University, Chicago) provided HeLa cells and the HSV reporter viruses listed here. HSV1 virus strain carrying the lacZ gene of E. coli and capable of expressing β-galactosidase
as a reporter of entry included HSV-1(KOS) gL86.193-194 Polystyrene sulfonate standards
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(PSS) (4-33 kDa) were from Sigma (St. Louis, MO). Other chemicals and solvents used
in the work were purchased from either Sigma-Aldrich (St. Louis, MO) or Fisher
(Agawam, MA).

4.3.2 Synthesis of Carboxylated Lignin Polymers
The lignin polymers from caffeic acid and ferulic acid monomers, CD and FD,
respectively, were prepared in a manner following earlier work.123-124 Briefly, caffeic acid
or ferulic acid (25 mM, 200 mL) and H2O2 (75 mM, 100 mL) were added dropwise to a
50 mL solution of 10 mg HRP in 10 mM sodium phosphate buffer, pH 8.0, over a period
of 5 h at room temperature in dark. Three additional aliquots H2O2 (75 mM, 100 mL)
were added over the next 72 h. At the end of polymerization the solution was freeze-dried
to obtain approximately 2 g of CD and FD polymers.

4.3.3 Fractionation of CD and FD Using Centrifugal Filtration.
The polymerization reaction mixture (~2 g) was dissolved in deionized water (8 mL) and
filtered through Millipore filter (NMWC 30 kDa) at 4000 g. Filtration was continued
until the retentate volume was approximately 200 μL. This process was repeated three
more times and the final retentate was labeled as F30 fraction. The filtrates from the
above process were pooled, lyophilized, redissolved in deionized water and then further
fractionated in the manner described above using a 10 kDa filter. The retentate so
obtained was labeled as F10 fraction. This process was repeated to obtain F5 and F3
fractions using 5 and 3 kDa membranes. The retentates were collected and lyophilized to
obtain four fractions in yields of 15-20, 5-8, 3-5, and 1-2%, respectively.
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4.3.4 Determination of Molecular Weight of Carboxylated Lignin Fractions
The number and weight average molecular weight of CD and FD fractions was measured
using gel permeation chromatography (GPC) on a Shimadzu chromatography system
composed of LC10Ai pumps and a SPD-10A VP UV-vis detector controlled by a SCL10A VP system controller connected to a computer. Each fraction was analyzed using
Phenogel 5 μ (Phenomenex, Torrance, CA, 7.6 mm i.d. x 300 mm). The mobile phase
consisted of 100% tetrahydrofuran at a constant flow rate of 0.7 mL/min. Polystyrene
standards, caffeic acid, and ferulic acid were used for calibration purposes. The
relationship between logarithm of the molecular weight and the elution volume (V) of the
standards was found to be linear with a correlation coefficient of 0.99. The wavelength of
detection for CD and FD fractions was set at 280 nm. Each chromatogram was sliced into
1000 time periods providing 1000 MR with the corresponding absorbance (A) values.
These values were used to calculate number average molecular weight (MN), weight
average molecular weight (MW) and polydispersity (P) parameters from equations 1, 2,
and 3, respectively, for each CD and FD fraction.

MN =

∑ Ai × Mi
∑ Ai

∑ Ai × Mi2
MW =
∑ Ai × Mi

…… (1)

P=

MW
MN
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…… (3)

…… (2)

4.3.5 Assay for HSV-1 Entry into Cells
Assays for infection of cells were based on the quantification of β-galactosidase
expressed by the mutant HSV viral genome containing the lacZ gene, as described
earlier.195-196 HeLa cells were grown in 96-well tissue culture dishes (2-4 x 104
cells/well), washed after 16 h of growth, and exposed to 10 plaque forming units (PFU)
per cell of the HSV virus in 50 μL of phosphate-buffered saline (PBS) containing glucose
and 1% calf serum for 6 h at 37 °C. To test for inhibitory activity, the sulfated
compounds were simultaneously added to this 50 μL medium in varying amounts ranging
from 0 to 2 μg. Following incubation, the cells were solubilized in 100 μL of PBS
containing 0.5% NP-40 and 10 mM ONPG. The initial rate of hydrolysis of the substrate
was monitored spectrophotometrically at 410 nm, which corresponds to the expressed
level of β-galactosidase within HeLa cell. The initial rate of hydrolysis of the substrate in
the absence of any added antagonist was used as the control and assigned a value of
100% HSV infection. Assays were performed in duplicate. Logistic equation 4 was used
to fit the dose-dependence of HSV infection to obtain the IC50.

Y = YO +

YM − YO

…... (4)

1 + 10(log[L]O − log IC50) × HC

In this equation, Y is the observed β-galactosidase activity (in %) in the presence of
carboxylated lignin (L) to that in its absence, YM and Y0 are the maximum and minimum

113

possible values of the β-galactosidase activity, IC50 is the concentration of L that results
in 50% antagonism of HSV-1, and HC is the Hill Cooperativity Index.

4.4

Results and Discussion

4.4.1 Caffeic and Ferulic Acids Polymerize with Ease To Generate Long Chains
Enzymatic polymerization of phenylpropenoid monomers to produce synthetic lignins
has been explored for a long time.197-201 Yet, previous reports on the oxidative coupling
of 4-hydroxycinnamic acids resulted only in oligomers with an average chain length of
less than three monomers.202-203 HRP-catalyzed polymerization of caffeic and ferulic acid
monomers at pH 8.0 with gradual addition of H2O2 over a period of more than 3 days
resulted in CD and FD polymers, respectively, in nearly quantitative yields (See figure
43). The MN and MW values of these polymeric mixtures, measured using GPC, were
found to be 4264 and 13272 Da for CD and 5322 and 11525 Da for FD (Table 15). These
values indicate that CD is more polydisperse and probably more heterogeneous than FD.
The average chain length of the two polymers was found to be 12 (CD) and 29 (FD). This
is the first report of such long polymers obtained through enzymatic polymerization of 4hydroxycinnamic acids. A probable reason for the higher level of polymerization is the
higher concentration of enzyme used in the reaction as well as the prolonged addition of
the oxidant.
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Table 15. Physical Properties of Size Fractionated Carboxylated Lignins

a

Number, weight, and peak average molecular weights were obtained by GPC analysis.
Polydispersity. cThe peak average chain length was calculated from the ratio of MP and
molecular weight of the two monomers. Numbers in brackets refer to the range of chain lengths
(see Experimental Methods).
b

4.4.2 CD and FD Are Less Globular than Natural Lignins
To assess the size dependence of putative antiviral activity of CD and FD, the two
polymeric mixtures were separated into four fractions of varying sizes using 3K, 5K,
10K, and 30K membrane-based centrifugal filtration. The GPC profiles of fractions were
found to be broad and reasonably symmetrical (figure 44). This implied that each
fraction contained nearly all types of chains. For example, although the average chain
length of FD3 and CD3 is 3.6 and 4.7, both fractions contain chains as long as 27 and 12
units, respectively (Table 15). Thus, the difference between the membrane-separated
fractions arises primarily due to chains being present in different proportions. A probable
explanation for why high molecular weight chains are present in CD3 and FD3 fractions
is that carboxylated lignins are more linear polymers than natural lignins. The random
oxidative coupling mechanism of enzymatic polymerization affords chain elongation
along nonlinear centers resulting in multidimensional polymerization189-190 which can
generate globular structures. Globular structures typically cannot pass through molecular
membranes or sieves. In contrast, linear structures can pass through sieves through
115

reptile-like motion. Thus, carboxylated lignins appear to be less globular than natural
lignins. This is important because greater the linearity of the lignin polymer greater is its
probability of mimicking HS, which has a 100% linear structure.

The MN, MW, and polydispersity (P) values calculated from the GPC profiles confirm the
above conclusions. The MN values ranged from 1052 to 7558, while MW was found to be
in the range of 2084 and 16464 (Table 15). The molecular weight at the peak maximum
(MP) was found to more closely resemble MN than MW suggesting a larger proportion of
smaller chains. The average chain length varied from 3.6 to 39.9 for FD fractions, while
it was between 4.7 and 12.1 oligomeric units for CD fractions (Table 15). This implies
that the chain length range was found to be much greater for FD (~11-fold) than for CD
(2.5-fold).

Figure 44. Normalized GPC profiles of fractions CD3 through CD30 obtained from
membrane-based centrifugal filtration of CD mixture.
A280 refers to the absorbance at 280 nm. The profiles for FD fractions were similar (not shown).
See Experimental Methods for details.
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4.4.3 CD and FD are Potent Antagonists of HSV-1 Entry into Cells.
The ability of CD and FD to prevent the entry of HSV-1 particles into mammalian cells
was studied using a standard cellular assay.204-205 In this assay, HeLa cells were exposed
to a reporter HSV-1 containing the lacZ gene in the presence and absence of CD, FD, and
their size fractionated preparations. The large size and significant anionic character of the
lignins prevents them from entering the mammalian cell, while the viral particle is
internalized through the concerted action of multiple cellular receptors, including
HS.202,203 Assuming CD and FD mimic cell-membrane-bound HS, the lignins would
competitively reduce the levels of the virus internalized by HeLa cells. Thus, the βgalactosidase activity of the internalized HSV-1 serves as a measure of the activity of
lignins in preventing viral entry.
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Figure 45. Profile of HSV-1 entry into cells in the presence of FD3 (A) and CD5 (B) using a
β-galactosidase activity-based viral entry assay.
Profiles of other fractions were similar and not shown. IC50 values calculated from these profiles
are listed in Table 16. See Experimental Methods for details.
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Figure 45 shows the viral entry profile for two representative lignin fractions, FD3 and
CD5. The profiles for other fractions were similar (not shown). A concentrationdependent antagonism of entry of HSV-1 into HeLa was noted for all preparations, which
was fitted using the standard dose-response equation to calculate the concentration of
carboxylated lignin required for 50% antagonism (IC50; Table 16). For size-fractioned
carboxylated lignins FD and CD, the IC50 values were found to be in the range of 72 and
284 ng/mL, which correspond to nanomolar potencies (13-56 nM). This indicates that our
new carboxylated lignin scaffold is highly effective in preventing the entry of HSV-1.

Table 16. Inhibition of HSV-1 Entry into Mammalian Cells by Size-Fractionated
Carboxylated Lignins CD and FDa

a

The IC50 values are concentrations of carboxylated lignins that result in 50% reduction in level of
HSV-1 entry. IC50 and HC values were obtained through nonlinear regression analysis of viral
entry data in the presence and absence of carboxylated lignins (see Experimental Methods).
b
Calculated using MW values from Table 15. cErrors represent ±2 S.E.

A closer look reveals that FD fractions are typically more potent than corresponding CD
fractions (Table 16). For example, FD3 is approximately 2-fold more potent than CD3.
Another difference between the two polymers appears in the Hill Cooperativity indices.
Whereas FD fractions display a HC of ~1, CD fractions show a value of ~0.5. In a
traditional multisite interaction of a macromolecule with its receptor, HC corresponds to
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cooperativity of interaction. A value of 1.0 implies no cooperativity, while values less
than 1.0 imply negative cooperativity. It is difficult to ascribe the phenomenon of
cooperativity in the antagonism of HSV-1 by CD and FD because both are heterogeneous
and polydisperse. Rather, HC values may reflect the degree of structural complexity of
the mixture, which can generate many different types of ligand – receptor complexes.
This possibility is greater for CD due to the presence of an additional -OH group that is
known to be more reactive than the corresponding -OMe in FD.

The potency of inhibition is minimally affected for FD fractions despite the change in
their molecular weights. For example, FD3 exhibits an IC50 of 13 nM, which is not
different from the value of 17 nM for FD30, although the average chain length increases
nearly 11-fold. The results for CD fractions are similar. Although the IC50 increases from
29 nM for the CD3 to 56 nM for CD10 and then decreases to 17 nM for CD30 (Table
16), the apparently nonlinear change is most likely due to its greater heterogeneity.

The viral inhibition profile of nonsulfated carboxylated lignins is dramatically different
from that of the sulfated lignins. For sulfated lignins, as the average chain length
increased so did their ability to antagonize viral entry.123,206 The reason for this size
dependence is the well-known statistical advantage offered by multiple binding sites
likely to be present in longer polymers. Yet, size-dependence is nearly completely
eliminated for carboxylated lignins. This implies that even the smallest FD and CD
chains are able to effectively prevent HSV-1 entry into cells, an observation that carries
major pharmaceutical value.
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4.5

Conclusions

Although a large number of polymers have been designed to inhibit viral entry into
mammalian cells, nearly each is a sulfated polysaccharide. Our success with sulfated
lignins led to the current work on carboxylated lignins, which do not contain any sulfate
group. The two enzymatically synthesized carboxylated lignins are polymers of
phenylpropanoid residues connected primarily through β-O-4 and β-5 linkages (figure
43). 123-124,188-189 Other linkages including β-β and 5-5 are also likely. These varying interresidue linkages and chain lengths introduce considerable structural heterogeneity in the
polymeric mixture. Structural heterogeneity is a major impediment in the drug discovery
process. Yet, it affords a high probability of discovering an initial lead, which may be
fine-tuned to result in a new pharmaceutical agent. The potent antagonism of HSV-1
entry into mammalian cells by all FD and CD fractions highlights the importance of
investigating scaffolds outside of the traditional saccharide scaffolds to discover novel
pharmaceuticals.

The IC50 value of HSV-1 inhibition by FD and CD fractions range from 8 to 56 nM
(Table 16). In comparison, our previous study with sulfated lignins demonstrated values
in the range of 1.7 to 1450 nM. This indicates that most carboxylated lignins are better
antagonists of HSV-1 infection of cells. More specifically, FD3 (MP = 698 Da) and CD3
(MP = 854 Da) displayed IC50 of 13 and 29 nM, respectively, which are 50-106-fold
lower than that found for the smallest sulfated lignin (MP = 1900 Da) earlier. This implies
that either carboxylated lignins are better at mimicking HS in comparison to sulfated
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lignins or that these new molecules possess a completely different mechanism of
antagonism of HSV-1.

A key discovery of this work is the high potency of FD (and CD) irrespective of chain
length. For example, FD3 is almost as antiviral as FD30 (Table 16). A plausible
explanation for this observation is that FD possesses discrete structure(s) that induce antiHSV-1 activity. The average chain length of FD3 is 3.6. This implies that small,
carboxylate group containing, FD-based molecules, for example, trimers with molecular
weight of 582 (194 x 3) are likely to exhibit significant anti-HSV-1 activity. In addition
to the small size, the presence of carboxylic acid groups in these polymers affords an
excellent route to design orally bioavailable anti-HSV-1 agents. Orally bioavailable
designs would contain ester protecting groups, which will undergo nonspecific hydrolysis
in vivo to release the small, carboxylated lignin-based inhibitor.

The carboxylated lignins studied here have additional advantages over sulfated lignins as
well as other polysaccharide-based agents. These polymers can be easily synthesized in
high yields in a fairly consistent manner. Chemical sulfation, on the other hand, is a
difficult reaction and is typically considerably variable.207-208 A large number of structural
variants of ferulic and caffeic acid monomers are available, which implies that new
agents can be studied for fine-tuning anti-HSV activity.

Overall, this study puts forward a carboxylated lignin polymer as a potent antagonist of
HSV-1 entry into mammalian cells. It can be expected that carboxylated lignins also
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antagonize the entry of other enveloped viruses, for example, HIV-1, dengue, Kaposi’s
sarcoma-associated herpes virus, and hepatitis C virus. In fact, a review of literature
suggests that effort to develop carboxylated lignins as anti-HIV agents has been made in
the past.209-211 Interestingly, the carboxylated lignins discussed here are about 1000-fold
more potent at inhibiting HSV-1 than those studied earlier as anti-HIV agents. The reason
for this massive selectivity in targeting HSV is not clear at the present time, but in
combination, the results present the possibility of preparing topical formulations of these
polymers for preventing infections arising from multiple pathogens.
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